Trial Outcomes & Findings for An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene (NCT NCT00932893)
NCT ID: NCT00932893
Last Updated: 2017-01-02
Results Overview
PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
347 participants
Primary outcome timeframe
Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)
Results posted on
2017-01-02
Participant Flow
Participant milestones
| Measure |
Crizotinib
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
Pemetrexed 500 mg per square meter (mg/m\^2) intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Overall Study
STARTED
|
173
|
174
|
|
Overall Study
Treated
|
172
|
171
|
|
Overall Study
COMPLETED
|
40
|
4
|
|
Overall Study
NOT COMPLETED
|
133
|
170
|
Reasons for withdrawal
| Measure |
Crizotinib
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
Pemetrexed 500 mg per square meter (mg/m\^2) intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Overall Study
Death
|
115
|
24
|
|
Overall Study
Lost to Follow-up
|
8
|
0
|
|
Overall Study
Withdrawal by Subject
|
5
|
2
|
|
Overall Study
Other
|
5
|
144
|
Baseline Characteristics
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Baseline characteristics by cohort
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Total
n=347 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
50.3 years
STANDARD_DEVIATION 13.1 • n=5 Participants
|
49.8 years
STANDARD_DEVIATION 13.0 • n=7 Participants
|
50.0 years
STANDARD_DEVIATION 13.0 • n=5 Participants
|
|
Gender
Female
|
98 Participants
n=5 Participants
|
95 Participants
n=7 Participants
|
193 Participants
n=5 Participants
|
|
Gender
Male
|
75 Participants
n=5 Participants
|
79 Participants
n=7 Participants
|
154 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)Population: Full analysis set (FAS) included all participants who were randomized to study treatment.
PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Progression-Free Survival (PFS)
|
7.7 months
Interval 6.0 to 8.8
|
3.0 months
Interval 2.6 to 4.3
|
SECONDARY outcome
Timeframe: Randomization until death (up to 4.5 years)Population: FAS included all participants who were randomized to study treatment.
OS: Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Overall Survival (OS)
|
21.7 months
Interval 18.9 to 30.5
|
21.9 months
Interval 16.8 to 26.0
|
SECONDARY outcome
Timeframe: Month 6, 12Population: FAS included all participants who were randomized to study treatment.
Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Overall Survival Probability at Months 6 and 12
Month 6
|
86.6 percent chance of survival
Interval 80.5 to 90.9
|
83.8 percent chance of survival
Interval 77.4 to 88.5
|
|
Overall Survival Probability at Months 6 and 12
Month 12
|
70.4 percent chance of survival
Interval 62.9 to 76.7
|
66.7 percent chance of survival
Interval 59.1 to 73.2
|
SECONDARY outcome
Timeframe: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)Population: FAS included all participants who were randomized to study treatment.
Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 millimeter \[mm\] short axis). PR: at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Objective response is based on independent radiology review.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Percentage of Participants With Objective Response (OR)
|
65.3 percentage of participants
Interval 57.7 to 72.4
|
19.5 percentage of participants
Interval 13.9 to 26.2
|
SECONDARY outcome
Timeframe: Week 6Population: FAS included all participants who were randomized to study treatment.
Disease control: participants with CR, PR, or stable disease (SD) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Disease control is based on independent radiology review.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Percentage of Participants With Disease Control at Week 6
|
81.5 percentage of participants
Interval 74.9 to 87.0
|
55.2 percentage of participants
Interval 47.5 to 62.7
|
SECONDARY outcome
Timeframe: Week 12Population: FAS included all participants who were randomized to study treatment.
Disease control: participants with CR, PR, or SD according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Outcome measures
| Measure |
Crizotinib
n=173 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=174 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Percentage of Participants With Disease Control at Week 12
|
64.2 percentage of participants
Interval 56.5 to 71.3
|
38.5 percentage of participants
Interval 31.2 to 46.2
|
SECONDARY outcome
Timeframe: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)Population: FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.02. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Outcome measures
| Measure |
Crizotinib
n=113 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=34 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Duration of Response (DR)
|
32.1 weeks
Interval 26.4 to 42.3
|
24.4 weeks
Interval 15.0 to 36.0
|
SECONDARY outcome
Timeframe: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)Population: FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.
Time from date of randomization to first documentation of objective tumor response. TTR was calculated for the subgroup of participants with objective tumor response. Objective tumor response was defined as CR or PR according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.
Outcome measures
| Measure |
Crizotinib
n=113 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=34 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Time to Tumor Response (TTR)
|
6.3 weeks
Interval 4.4 to 48.4
|
12.6 weeks
Interval 5.0 to 37.1
|
SECONDARY outcome
Timeframe: Pre-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 3, 5Population: Pharmacokinetic (PK) analysis population included all randomized participants who received at least 1 dose of study treatment and had 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants evaluable for this measure. n=participants evaluable at specific time points.
Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Outcome measures
| Measure |
Crizotinib
n=152 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Plasma Concentration of Crizotinib
Cycle 1 Day 1 (n=15)
|
NA nanogram per milliliter (ng/mL)
Standard Deviation NA
Data was not summarized since none of the participants had Ctrough values above lower limit of quantification (LLOQ).
|
—
|
|
Plasma Concentration of Crizotinib
Cycle 1 Day 15 (n=92)
|
298 nanogram per milliliter (ng/mL)
Standard Deviation 148
|
—
|
|
Plasma Concentration of Crizotinib
Cycle 2 Day 1 (n=62)
|
293 nanogram per milliliter (ng/mL)
Standard Deviation 154
|
—
|
|
Plasma Concentration of Crizotinib
Cycle 3 Day 1 (n=61)
|
306 nanogram per milliliter (ng/mL)
Standard Deviation 135
|
—
|
|
Plasma Concentration of Crizotinib
Cycle 5 Day 1 (n=47)
|
291 nanogram per milliliter (ng/mL)
Standard Deviation 156
|
—
|
SECONDARY outcome
Timeframe: Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 1, 2Population: ECG-evaluable population included all randomized participants who received at least 1 dose of study treatment, and had a baseline and at least 1 post-baseline ECG measurement.
QT interval corrected using Fridericia's formula (QTcF): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to \<480 msec, 480 msec to \<500 msec, and more than or equal to (\>=) 500 msec. A participant is reported only once under the maximum QTcF interval observed at any of the time-points. Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Outcome measures
| Measure |
Crizotinib
n=155 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Number of Participants With Categorical Maximum QTcF for Crizotinib
<450 msec
|
137 participants
|
—
|
|
Number of Participants With Categorical Maximum QTcF for Crizotinib
450 msec to <480 msec
|
9 participants
|
—
|
|
Number of Participants With Categorical Maximum QTcF for Crizotinib
480 msec to <500 msec
|
1 participants
|
—
|
|
Number of Participants With Categorical Maximum QTcF for Crizotinib
>=500 msec
|
8 participants
|
—
|
SECONDARY outcome
Timeframe: Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 2, end of treatment (up to 112 weeks)Population: The soluble biomarker-evaluable population includes patients from the SA population that received PF-02341066, who have an optional blood sample prior to dosing on Cycle 1 Day 1 and have at least 1 on-treatment soluble biomarker evaluation (Cycle 2 Day 1 and/or end of treatment).
Descriptive statistics (absolute value and change from baseline as measured by ratio to baseline) for each best overall response category (CR, PR, SD, PD or combined) have been used to summarize the data from optional soluble c-Met ectodomain assays for crizotinib treated patients.
Outcome measures
| Measure |
Crizotinib
n=172 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins
Baseline (N = 81)
|
1428.3 nanogram per milliliter (ng/mL)
Standard Deviation 363.9
|
—
|
|
Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins
Cycle 2 Day 1 6-hour post dose (N = 69)
|
1683.0 nanogram per milliliter (ng/mL)
Standard Deviation 325.6
|
—
|
|
Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins
End of treatment (N = 40)
|
1751.8 nanogram per milliliter (ng/mL)
Standard Deviation 327.9
|
—
|
SECONDARY outcome
Timeframe: Baseline up to end of treatment (up to 112 weeks)Population: Patient Reported Outcome (PRO) evaluable population included all randomized participants who received at least 1 dose of study treatment, and had a baseline and at least 1 post-baseline PRO assessment.
TTD in pain (pain in chest from European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer \[EORTC QLQ-LC13\]), dyspnea (from EORTC QLQ-LC13), or cough (from EORTC QLQ-LC13) symptoms was defined as the time from randomization to the earliest time the participant's score showed a 10 point or higher increase from baseline in any of the three symptoms from the instrument. The transformed score of pain, dyspnea, and cough symptom scales of EORTC QLQ-LC13 range from 0 to 100, greater scores = higher symptom severity.
Outcome measures
| Measure |
Crizotinib
n=162 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=151 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough
|
4.5 months
Interval 3.0 to 6.9
|
1.4 months
Interval 1.0 to 1.6
|
SECONDARY outcome
Timeframe: Baseline, Day (D) 1 of each cycle (C) until disease progression, end of treatment (EOT, up to 112 weeks)Population: FAS included all participants who were randomized to study treatment. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for specified time points for each arm group, respectively.
EORTC QLQ-C30: included global health status/quality of life (QoL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of QoL/functioning or higher score for symptom scale=greater degree of symptoms.
Outcome measures
| Measure |
Crizotinib
n=165 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=163 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C28D1 (n=11, 2)
|
21.2 units on a scale
Standard Deviation 16.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C15D1 (n=62, 16)
|
69.0 units on a scale
Standard Deviation 22.2
|
66.1 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C16D1 (n=53, 12)
|
69.7 units on a scale
Standard Deviation 18.1
|
63.2 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C17D1 (n=47, 11)
|
67.6 units on a scale
Standard Deviation 20.5
|
69.7 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C16D1 (n=53, 12)
|
13.8 units on a scale
Standard Deviation 17.8
|
19.4 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C17D1 (n=46, 11)
|
14.5 units on a scale
Standard Deviation 20.7
|
24.2 units on a scale
Standard Deviation 21.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C18D1 (n=45, 11)
|
14.1 units on a scale
Standard Deviation 16.6
|
24.2 units on a scale
Standard Deviation 26.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C19D1 (n=40, 9)
|
14.2 units on a scale
Standard Deviation 18.3
|
25.9 units on a scale
Standard Deviation 22.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C18D1 (n=44, 11)
|
65.7 units on a scale
Standard Deviation 19.9
|
70.5 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C19D1 (n=40, 9)
|
69.2 units on a scale
Standard Deviation 19.2
|
72.2 units on a scale
Standard Deviation 20.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C20D1 (n=35, 8)
|
64.3 units on a scale
Standard Deviation 20.6
|
60.4 units on a scale
Standard Deviation 21.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C21D1 (n=30, 8)
|
65.0 units on a scale
Standard Deviation 18.4
|
63.5 units on a scale
Standard Deviation 23.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C22D1 (n=24, 7)
|
70.8 units on a scale
Standard Deviation 19.3
|
64.3 units on a scale
Standard Deviation 24.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C23D1 (n=23, 4)
|
67.0 units on a scale
Standard Deviation 22.5
|
50.0 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C24D1 (n=20, 3)
|
67.1 units on a scale
Standard Deviation 18.8
|
55.6 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C25D1 (n=18, 3)
|
67.1 units on a scale
Standard Deviation 17.7
|
61.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C26D1 (n=14, 3)
|
60.7 units on a scale
Standard Deviation 22.0
|
55.6 units on a scale
Standard Deviation 12.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C27D1 (n=14, 2)
|
58.9 units on a scale
Standard Deviation 20.3
|
41.7 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C28D1 (n=11, 2)
|
66.7 units on a scale
Standard Deviation 18.3
|
54.2 units on a scale
Standard Deviation 17.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C29D1 (n=8, 2)
|
59.4 units on a scale
Standard Deviation 18.6
|
41.7 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C30D1 (n=8, 1)
|
64.6 units on a scale
Standard Deviation 19.3
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C31D1 (n=7, 0)
|
64.3 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C32D1 (n=6, 0)
|
59.7 units on a scale
Standard Deviation 17.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C33D1 (n=6, 0)
|
66.7 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C34D1 (n=5, 0)
|
68.3 units on a scale
Standard Deviation 14.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C35D1 (n=4, 0)
|
60.4 units on a scale
Standard Deviation 22.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C36D1 (n=1, 0)
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C37D1 (n=1, 0)
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C20D1 (n=35, 8)
|
10.5 units on a scale
Standard Deviation 17.7
|
33.3 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: Baseline (n=165, 163)
|
76.3 units on a scale
Standard Deviation 20.7
|
75.8 units on a scale
Standard Deviation 21.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C2D1 (n=155, 133)
|
79.2 units on a scale
Standard Deviation 20.9
|
73.5 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C3D1 (n=154, 106)
|
82.3 units on a scale
Standard Deviation 18.1
|
75.5 units on a scale
Standard Deviation 20.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C4D1 (n=135, 91)
|
83.8 units on a scale
Standard Deviation 16.2
|
76.6 units on a scale
Standard Deviation 20.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C5D1 (n=123, 74)
|
84.5 units on a scale
Standard Deviation 16.2
|
78.6 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C6D1 (n=120, 70)
|
86.2 units on a scale
Standard Deviation 16.7
|
80.7 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C7D1 (n=115, 52)
|
86.7 units on a scale
Standard Deviation 15.0
|
80.3 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C8D1 (n=111, 43)
|
86.5 units on a scale
Standard Deviation 16.3
|
81.6 units on a scale
Standard Deviation 18.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C9D1 (n=101, 37)
|
87.7 units on a scale
Standard Deviation 14.2
|
82.3 units on a scale
Standard Deviation 19.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C10D1 (n=94, 33)
|
87.9 units on a scale
Standard Deviation 14.8
|
81.8 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C11D1 (n=84, 25)
|
87.2 units on a scale
Standard Deviation 16.7
|
83.2 units on a scale
Standard Deviation 19.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C12D1 (n=76, 23)
|
88.1 units on a scale
Standard Deviation 15.3
|
79.7 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C13D1 (n=74, 21)
|
89.3 units on a scale
Standard Deviation 13.9
|
78.4 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C14D1 (n=66, 19)
|
89.0 units on a scale
Standard Deviation 14.3
|
80.0 units on a scale
Standard Deviation 21.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C15D1 (n=62, 16)
|
87.8 units on a scale
Standard Deviation 15.3
|
82.9 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C16D1 (n=53, 12)
|
89.3 units on a scale
Standard Deviation 11.5
|
81.1 units on a scale
Standard Deviation 19.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C17D1 (n=47, 11)
|
86.6 units on a scale
Standard Deviation 16.8
|
81.8 units on a scale
Standard Deviation 15.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C18D1 (n=45, 11)
|
88.4 units on a scale
Standard Deviation 13.3
|
82.4 units on a scale
Standard Deviation 16.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C19D1 (n=40, 9)
|
88.3 units on a scale
Standard Deviation 12.4
|
81.5 units on a scale
Standard Deviation 12.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C20D1 (n=35, 8)
|
87.6 units on a scale
Standard Deviation 12.7
|
79.2 units on a scale
Standard Deviation 17.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C21D1 (n=30, 8)
|
88.4 units on a scale
Standard Deviation 10.9
|
77.5 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C22D1 (n=24, 7)
|
90.6 units on a scale
Standard Deviation 8.3
|
78.1 units on a scale
Standard Deviation 24.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C23D1 (n=23, 4)
|
88.0 units on a scale
Standard Deviation 13.1
|
60.0 units on a scale
Standard Deviation 27.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C24D1 (n=20, 3)
|
85.0 units on a scale
Standard Deviation 14.0
|
64.4 units on a scale
Standard Deviation 32.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C25D1 (n=18, 3)
|
87.4 units on a scale
Standard Deviation 11.6
|
60.0 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C26D1 (n=14, 3)
|
80.5 units on a scale
Standard Deviation 25.3
|
62.2 units on a scale
Standard Deviation 30.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C27D1 (n=14, 2)
|
78.6 units on a scale
Standard Deviation 27.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C28D1 (n=11, 2)
|
81.8 units on a scale
Standard Deviation 24.1
|
60.0 units on a scale
Standard Deviation 18.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C29D1 (n=8, 2)
|
85.0 units on a scale
Standard Deviation 15.0
|
46.7 units on a scale
Standard Deviation 28.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C30D1 (n=8, 1)
|
82.5 units on a scale
Standard Deviation 21.4
|
26.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C31D1 (n=7, 0)
|
83.8 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C32D1 (n=6, 0)
|
88.9 units on a scale
Standard Deviation 9.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C33D1 (n=6, 0)
|
90.0 units on a scale
Standard Deviation 7.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C34D1 (n=5, 0)
|
85.3 units on a scale
Standard Deviation 7.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C35D1 (n=4, 0)
|
91.7 units on a scale
Standard Deviation 3.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C36D1 (n=1, 0)
|
86.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: C37D1 (n=1, 0)
|
86.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: Baseline (n=165, 163)
|
69.3 units on a scale
Standard Deviation 28.7
|
66.6 units on a scale
Standard Deviation 30.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C2D1 (n=155, 133)
|
73.8 units on a scale
Standard Deviation 28.9
|
64.7 units on a scale
Standard Deviation 29.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C3D1 (n=154, 106)
|
74.4 units on a scale
Standard Deviation 28.6
|
65.3 units on a scale
Standard Deviation 27.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C4D1 (n=134, 91)
|
77.9 units on a scale
Standard Deviation 25.7
|
67.2 units on a scale
Standard Deviation 27.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C5D1 (n=123, 74)
|
78.2 units on a scale
Standard Deviation 24.3
|
69.6 units on a scale
Standard Deviation 27.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C6D1 (n=120, 70)
|
80.0 units on a scale
Standard Deviation 24.1
|
69.5 units on a scale
Standard Deviation 26.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C7D1 (n=115, 52)
|
81.7 units on a scale
Standard Deviation 22.6
|
72.1 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C8D1 (n=111, 43)
|
80.4 units on a scale
Standard Deviation 23.9
|
75.2 units on a scale
Standard Deviation 28.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C9D1 (n=101, 37)
|
80.9 units on a scale
Standard Deviation 25.8
|
76.6 units on a scale
Standard Deviation 27.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C10D1 (n=94, 33)
|
81.6 units on a scale
Standard Deviation 23.1
|
75.3 units on a scale
Standard Deviation 28.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C11D1 (n=84, 25)
|
81.3 units on a scale
Standard Deviation 23.8
|
75.3 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C12D1 (n=76, 23)
|
81.6 units on a scale
Standard Deviation 23.2
|
72.5 units on a scale
Standard Deviation 29.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C13D1 (n=74, 21)
|
80.2 units on a scale
Standard Deviation 25.5
|
68.3 units on a scale
Standard Deviation 32.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C14D1 (n=66, 19)
|
83.8 units on a scale
Standard Deviation 21.3
|
68.4 units on a scale
Standard Deviation 30.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C15D1 (n=62, 16)
|
80.6 units on a scale
Standard Deviation 24.0
|
77.1 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C16D1 (n=53, 12)
|
84.0 units on a scale
Standard Deviation 19.0
|
69.4 units on a scale
Standard Deviation 34.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C17D1 (n=47, 11)
|
77.7 units on a scale
Standard Deviation 25.4
|
71.2 units on a scale
Standard Deviation 38.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C18D1 (n=45, 11)
|
80.0 units on a scale
Standard Deviation 22.4
|
71.2 units on a scale
Standard Deviation 31.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C19D1 (n=40, 9)
|
82.1 units on a scale
Standard Deviation 19.4
|
74.1 units on a scale
Standard Deviation 29.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C20D1 (n=35, 8)
|
81.9 units on a scale
Standard Deviation 17.8
|
70.8 units on a scale
Standard Deviation 36.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C21D1 (n=30, 8)
|
80.0 units on a scale
Standard Deviation 24.1
|
66.7 units on a scale
Standard Deviation 32.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C22D1 (n=24, 7)
|
84.7 units on a scale
Standard Deviation 19.0
|
67.9 units on a scale
Standard Deviation 33.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C23D1 (n=23, 4)
|
76.8 units on a scale
Standard Deviation 26.9
|
37.5 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C24D1 (n=20, 3)
|
80.8 units on a scale
Standard Deviation 24.3
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C25D1 (n=18, 3)
|
87.0 units on a scale
Standard Deviation 19.4
|
44.4 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C26D1 (n=14, 3)
|
75.0 units on a scale
Standard Deviation 29.1
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C27D1 (n=14, 2)
|
69.0 units on a scale
Standard Deviation 35.1
|
25.0 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C28D1 (n=11, 2)
|
77.3 units on a scale
Standard Deviation 33.6
|
25.0 units on a scale
Standard Deviation 35.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C29D1 (n=8, 2)
|
77.1 units on a scale
Standard Deviation 34.4
|
25.0 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C30D1 (n=8, 1)
|
77.1 units on a scale
Standard Deviation 34.4
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C31D1 (n=7, 0)
|
71.4 units on a scale
Standard Deviation 36.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C32D1 (n=6, 0)
|
86.1 units on a scale
Standard Deviation 12.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C33D1 (n=6, 0)
|
88.9 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C34D1 (n=5, 0)
|
96.7 units on a scale
Standard Deviation 7.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C35D1 (n=4, 0)
|
91.7 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C36D1 (n=1, 0)
|
100.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: C37D1 (n=1, 0)
|
100.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: Baseline (n=165, 162)
|
74.5 units on a scale
Standard Deviation 21.3
|
73.7 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C2D1 (n=155, 133)
|
83.1 units on a scale
Standard Deviation 18.7
|
77.7 units on a scale
Standard Deviation 19.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C3D1 (n=154, 106)
|
83.3 units on a scale
Standard Deviation 16.7
|
77.9 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C4D1 (n=135, 90)
|
84.1 units on a scale
Standard Deviation 17.3
|
80.5 units on a scale
Standard Deviation 18.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C5D1 (n=123, 74)
|
83.0 units on a scale
Standard Deviation 19.1
|
79.8 units on a scale
Standard Deviation 19.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C6D1 (n=120, 70)
|
85.3 units on a scale
Standard Deviation 17.8
|
81.2 units on a scale
Standard Deviation 19.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C7D1 (n=115, 52)
|
86.4 units on a scale
Standard Deviation 16.5
|
81.9 units on a scale
Standard Deviation 17.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C8D1 (n=111, 43)
|
83.9 units on a scale
Standard Deviation 19.8
|
81.6 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C9D1 (n=101, 37)
|
84.4 units on a scale
Standard Deviation 19.0
|
82.4 units on a scale
Standard Deviation 19.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C10D1 (n=94, 33)
|
87.2 units on a scale
Standard Deviation 16.8
|
81.8 units on a scale
Standard Deviation 21.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C11D1 (n=84,25)
|
86.1 units on a scale
Standard Deviation 16.7
|
85.0 units on a scale
Standard Deviation 17.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C12D1 (n=76, 23)
|
85.3 units on a scale
Standard Deviation 18.6
|
84.8 units on a scale
Standard Deviation 18.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C13D1 (n=74, 21)
|
84.9 units on a scale
Standard Deviation 19.0
|
80.6 units on a scale
Standard Deviation 19.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C14D1 (n=66, 19)
|
84.5 units on a scale
Standard Deviation 19.9
|
81.6 units on a scale
Standard Deviation 21.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C15D1 (n=62, 16)
|
86.3 units on a scale
Standard Deviation 18.0
|
82.3 units on a scale
Standard Deviation 18.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C16D1 (n=53, 12)
|
85.8 units on a scale
Standard Deviation 17.6
|
77.8 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C17D1 (n=47, 11)
|
85.6 units on a scale
Standard Deviation 22.0
|
79.5 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C18D1 (n=44, 11)
|
86.4 units on a scale
Standard Deviation 17.2
|
75.8 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C19D1 (n=40, 9)
|
87.3 units on a scale
Standard Deviation 16.0
|
81.5 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C20D1 (n=35, 8)
|
83.8 units on a scale
Standard Deviation 17.5
|
82.3 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C21D1 (n=30, 8)
|
84.5 units on a scale
Standard Deviation 17.1
|
80.2 units on a scale
Standard Deviation 29.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C22D1 (n=24, 7)
|
83.7 units on a scale
Standard Deviation 21.6
|
78.6 units on a scale
Standard Deviation 24.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C23D1 (n=23, 4)
|
84.1 units on a scale
Standard Deviation 19.8
|
70.8 units on a scale
Standard Deviation 21.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C24D1 (n=20, 3)
|
87.9 units on a scale
Standard Deviation 16.1
|
66.7 units on a scale
Standard Deviation 30.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C25D1 (n=18, 3)
|
81.5 units on a scale
Standard Deviation 19.5
|
72.2 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C26D1 (n=14, 3)
|
73.2 units on a scale
Standard Deviation 28.3
|
72.2 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C27D1 (n=14, 2)
|
70.8 units on a scale
Standard Deviation 27.3
|
58.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C28D1 (n=11, 2)
|
81.1 units on a scale
Standard Deviation 27.2
|
58.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C29D1 (n=8, 2)
|
86.5 units on a scale
Standard Deviation 15.4
|
54.2 units on a scale
Standard Deviation 5.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C30D1 (n=8, 1)
|
84.4 units on a scale
Standard Deviation 25.0
|
58.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C31D1 (n=7, 0)
|
76.2 units on a scale
Standard Deviation 28.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C32D1 (n=6, 0)
|
87.5 units on a scale
Standard Deviation 17.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C33D1 (n=6, 0)
|
90.3 units on a scale
Standard Deviation 13.4
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C34D1 (n=5, 0)
|
91.7 units on a scale
Standard Deviation 14.4
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C35D1 (n=4, 0)
|
83.3 units on a scale
Standard Deviation 20.4
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C36D1 (n=1, 0)
|
58.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: C37D1 (n=1, 0)
|
58.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: Baseline (n=165, 162)
|
85.6 units on a scale
Standard Deviation 18.3
|
83.6 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C2D1 (n=155, 133)
|
85.5 units on a scale
Standard Deviation 18.9
|
84.5 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C3D1 (n=154, 106)
|
87.0 units on a scale
Standard Deviation 15.7
|
83.8 units on a scale
Standard Deviation 20.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C4D1 (n=135, 90)
|
88.1 units on a scale
Standard Deviation 15.6
|
82.6 units on a scale
Standard Deviation 20.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C5D1 (n=123, 74)
|
88.9 units on a scale
Standard Deviation 14.4
|
82.7 units on a scale
Standard Deviation 22.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C6D1 (n=120, 70)
|
87.5 units on a scale
Standard Deviation 15.3
|
83.8 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C7D1 (n=115, 52)
|
86.7 units on a scale
Standard Deviation 15.6
|
85.3 units on a scale
Standard Deviation 18.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C8D1 (n=111, 43)
|
87.8 units on a scale
Standard Deviation 14.7
|
82.2 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C9D1 (n=101, 37)
|
88.3 units on a scale
Standard Deviation 16.6
|
84.7 units on a scale
Standard Deviation 21.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C10D1 (n=94, 33)
|
89.2 units on a scale
Standard Deviation 16.0
|
80.8 units on a scale
Standard Deviation 22.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C11D1 (n=84, 25)
|
87.9 units on a scale
Standard Deviation 14.9
|
85.3 units on a scale
Standard Deviation 19.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C12D1 (n=76, 23)
|
89.5 units on a scale
Standard Deviation 14.4
|
80.4 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C13D1 (n=74, 21)
|
88.5 units on a scale
Standard Deviation 15.6
|
79.4 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C14D1 (n=66, 19)
|
88.9 units on a scale
Standard Deviation 14.7
|
81.6 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C15D1 (n=62, 16)
|
87.6 units on a scale
Standard Deviation 15.4
|
84.4 units on a scale
Standard Deviation 18.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C16D1 (n=53, 12)
|
87.4 units on a scale
Standard Deviation 14.2
|
72.2 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C17D1 (n=47, 11)
|
85.1 units on a scale
Standard Deviation 15.2
|
75.8 units on a scale
Standard Deviation 21.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C18D1 (n=44, 11)
|
88.3 units on a scale
Standard Deviation 14.6
|
75.8 units on a scale
Standard Deviation 25.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C19D1 (n=40, 9)
|
87.5 units on a scale
Standard Deviation 14.5
|
70.4 units on a scale
Standard Deviation 23.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C20D1 (n=35, 8)
|
85.7 units on a scale
Standard Deviation 15.2
|
72.9 units on a scale
Standard Deviation 23.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C21D1 (n=30, 8)
|
85.6 units on a scale
Standard Deviation 15.0
|
72.9 units on a scale
Standard Deviation 23.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C22D1 (n=24, 7)
|
86.1 units on a scale
Standard Deviation 15.3
|
69.0 units on a scale
Standard Deviation 24.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C23D1 (n=23, 4)
|
85.5 units on a scale
Standard Deviation 14.5
|
58.3 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C24D1 (n=20, 3)
|
85.8 units on a scale
Standard Deviation 19.7
|
61.1 units on a scale
Standard Deviation 34.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C25D1 (n=18, 3)
|
86.1 units on a scale
Standard Deviation 15.4
|
55.6 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C26D1 (n=14, 3)
|
81.0 units on a scale
Standard Deviation 26.0
|
61.1 units on a scale
Standard Deviation 34.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C27D1 (n=14, 2)
|
76.2 units on a scale
Standard Deviation 25.9
|
41.7 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C28D1 (n=11, 2)
|
78.8 units on a scale
Standard Deviation 21.2
|
41.7 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C29D1 (n=8, 2)
|
87.5 units on a scale
Standard Deviation 11.8
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C30D1 (n=8, 1)
|
83.3 units on a scale
Standard Deviation 23.6
|
16.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C31D1 (n=7, 0)
|
81.0 units on a scale
Standard Deviation 20.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C32D1 (n=6, 0)
|
83.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C33D1 (n=6, 0)
|
86.1 units on a scale
Standard Deviation 16.4
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C34D1 (n=5, 0)
|
90.0 units on a scale
Standard Deviation 9.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C35D1 (n=4, 0)
|
95.8 units on a scale
Standard Deviation 8.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C36D1 (n=1, 0)
|
100.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: C37D1 (n=1, 0)
|
83.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: Baseline (n=165, 162)
|
68.0 units on a scale
Standard Deviation 27.7
|
67.1 units on a scale
Standard Deviation 29.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C2D1 (n=155, 133)
|
75.9 units on a scale
Standard Deviation 25.1
|
69.5 units on a scale
Standard Deviation 28.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C3D1 (n=154, 106)
|
78.5 units on a scale
Standard Deviation 24.0
|
72.5 units on a scale
Standard Deviation 26.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C4D1 (n=135, 90)
|
79.4 units on a scale
Standard Deviation 23.9
|
71.7 units on a scale
Standard Deviation 26.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C5D1 (n=123, 74)
|
79.4 units on a scale
Standard Deviation 23.8
|
74.5 units on a scale
Standard Deviation 27.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C6D1 (n=120, 70)
|
81.8 units on a scale
Standard Deviation 22.1
|
76.4 units on a scale
Standard Deviation 27.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C7D1 (n=115, 52)
|
82.3 units on a scale
Standard Deviation 21.8
|
77.9 units on a scale
Standard Deviation 24.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C8D1 (n=111, 43)
|
82.0 units on a scale
Standard Deviation 21.3
|
77.5 units on a scale
Standard Deviation 24.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C9D1 (n=101, 37)
|
80.4 units on a scale
Standard Deviation 24.7
|
80.2 units on a scale
Standard Deviation 21.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C10D1 (n=94, 33)
|
81.9 units on a scale
Standard Deviation 25.1
|
76.3 units on a scale
Standard Deviation 27.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C11D1 (n=84, 25)
|
81.9 units on a scale
Standard Deviation 23.0
|
78.7 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C12D1 (n=76, 23)
|
82.0 units on a scale
Standard Deviation 23.5
|
71.0 units on a scale
Standard Deviation 31.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C13D1 (n=74, 21)
|
81.8 units on a scale
Standard Deviation 24.7
|
71.4 units on a scale
Standard Deviation 28.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C14D1 (n=66, 19)
|
81.3 units on a scale
Standard Deviation 23.8
|
69.3 units on a scale
Standard Deviation 34.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C15D1 (n=62, 16)
|
81.5 units on a scale
Standard Deviation 25.6
|
74.0 units on a scale
Standard Deviation 28.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C16D1 (n=53, 12)
|
82.7 units on a scale
Standard Deviation 21.9
|
65.3 units on a scale
Standard Deviation 35.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C17D1 (n=47, 11)
|
81.9 units on a scale
Standard Deviation 24.8
|
69.7 units on a scale
Standard Deviation 33.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C18D1 (n=44, 11)
|
82.6 units on a scale
Standard Deviation 22.7
|
65.2 units on a scale
Standard Deviation 35.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C19D1 (n=40, 9)
|
84.6 units on a scale
Standard Deviation 22.8
|
64.8 units on a scale
Standard Deviation 31.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C20D1 (n=35, 8)
|
82.9 units on a scale
Standard Deviation 23.7
|
70.8 units on a scale
Standard Deviation 33.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C21D1 (n=30, 8)
|
82.8 units on a scale
Standard Deviation 24.2
|
64.6 units on a scale
Standard Deviation 36.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C22D1 (n=24, 7)
|
82.6 units on a scale
Standard Deviation 23.8
|
65.5 units on a scale
Standard Deviation 39.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C23D1 (n=23, 4)
|
84.4 units on a scale
Standard Deviation 23.9
|
41.7 units on a scale
Standard Deviation 50.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C24D1 (n=20, 3)
|
84.2 units on a scale
Standard Deviation 27.3
|
61.1 units on a scale
Standard Deviation 53.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C25D1 (n=18, 3)
|
89.8 units on a scale
Standard Deviation 19.1
|
50.0 units on a scale
Standard Deviation 50.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C26D1 (n=14, 3)
|
78.6 units on a scale
Standard Deviation 28.8
|
50.0 units on a scale
Standard Deviation 50.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C27D1 (n=14, 2)
|
85.7 units on a scale
Standard Deviation 15.8
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C28D1 (n=11, 2)
|
83.3 units on a scale
Standard Deviation 26.9
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C29D1 (n=8, 2)
|
83.3 units on a scale
Standard Deviation 25.2
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C30D1 (n=8, 1)
|
85.4 units on a scale
Standard Deviation 24.3
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C31D1 (n=7, 0)
|
73.8 units on a scale
Standard Deviation 38.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C32D1 (n=6, 0)
|
83.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C33D1 (n=6, 0)
|
94.4 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C34D1 (n=5, 0)
|
96.7 units on a scale
Standard Deviation 7.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C35D1 (n=4, 0)
|
91.7 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C36D1 (n=1, 0)
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Functioning: C37D1 (n=1, 0)
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: Baseline (n=165, 163)
|
38.3 units on a scale
Standard Deviation 24.4
|
36.1 units on a scale
Standard Deviation 25.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C2D1 (n=155, 133)
|
31.4 units on a scale
Standard Deviation 23.4
|
39.5 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C3D1 (n=154, 106)
|
30.8 units on a scale
Standard Deviation 24.1
|
39.4 units on a scale
Standard Deviation 24.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C4D1 (n=135, 91)
|
27.1 units on a scale
Standard Deviation 22.3
|
34.1 units on a scale
Standard Deviation 22.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C5D1 (n=123, 74)
|
24.7 units on a scale
Standard Deviation 19.8
|
31.5 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C6D1 (n=120, 70)
|
24.6 units on a scale
Standard Deviation 19.3
|
31.0 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C7D1 (n=115, 52)
|
23.9 units on a scale
Standard Deviation 19.8
|
27.6 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C8D1 (n=111, 43)
|
23.2 units on a scale
Standard Deviation 18.9
|
26.6 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C9D1 (n=101, 37)
|
22.9 units on a scale
Standard Deviation 21.7
|
28.5 units on a scale
Standard Deviation 26.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C10D1 (n=94, 33)
|
21.4 units on a scale
Standard Deviation 20.0
|
28.6 units on a scale
Standard Deviation 27.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C11D1 (n=84, 25)
|
22.1 units on a scale
Standard Deviation 19.6
|
22.2 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C12D1 (n=76, 23)
|
21.9 units on a scale
Standard Deviation 22.9
|
26.1 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C13D1 (n=74, 21)
|
23.3 units on a scale
Standard Deviation 21.3
|
27.5 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C14D1 (n=66, 19)
|
21.7 units on a scale
Standard Deviation 21.7
|
28.1 units on a scale
Standard Deviation 26.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C15D1 (n=62, 16)
|
20.8 units on a scale
Standard Deviation 22.5
|
24.3 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C16D1 (n=53, 12)
|
22.2 units on a scale
Standard Deviation 18.0
|
24.1 units on a scale
Standard Deviation 21.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C17D1 (n=47, 11)
|
23.4 units on a scale
Standard Deviation 20.0
|
23.2 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C18D1 (n=45, 11)
|
21.5 units on a scale
Standard Deviation 18.3
|
27.3 units on a scale
Standard Deviation 22.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C19D1 (n=40, 9)
|
20.8 units on a scale
Standard Deviation 18.7
|
24.7 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C20D1 (n=35, 8)
|
24.4 units on a scale
Standard Deviation 19.2
|
27.8 units on a scale
Standard Deviation 26.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C21D1 (n=30, 8)
|
23.9 units on a scale
Standard Deviation 17.8
|
25.7 units on a scale
Standard Deviation 27.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C22D1 (n=24, 7)
|
23.6 units on a scale
Standard Deviation 16.2
|
27.0 units on a scale
Standard Deviation 23.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C23D1 (n=23, 4)
|
25.1 units on a scale
Standard Deviation 19.3
|
47.2 units on a scale
Standard Deviation 14.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C24D1 (n=20, 3)
|
24.4 units on a scale
Standard Deviation 18.9
|
40.7 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C25D1 (n=18, 3)
|
24.7 units on a scale
Standard Deviation 16.0
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C26D1 (n=14, 3)
|
30.2 units on a scale
Standard Deviation 25.6
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C27D1 (n=14, 2)
|
35.7 units on a scale
Standard Deviation 25.1
|
55.6 units on a scale
Standard Deviation 15.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C28D1 (n=11, 2)
|
28.3 units on a scale
Standard Deviation 22.4
|
38.9 units on a scale
Standard Deviation 7.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C29D1 (n=8, 2)
|
30.6 units on a scale
Standard Deviation 22.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C30D1 (n=8, 1)
|
26.4 units on a scale
Standard Deviation 24.4
|
55.6 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C31D1 (n=7, 0)
|
28.6 units on a scale
Standard Deviation 16.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C32D1 (n=6, 0)
|
25.9 units on a scale
Standard Deviation 5.7
|
NA units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C33D1 (n=6, 0)
|
18.5 units on a scale
Standard Deviation 11.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C34D1 (n=5, 0)
|
15.6 units on a scale
Standard Deviation 16.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C35D1 (n=4, 0)
|
27.8 units on a scale
Standard Deviation 14.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C36D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: C37D1 (n=1, 0)
|
11.1 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: Baseline (n=165, 163)
|
8.4 units on a scale
Standard Deviation 14.4
|
11.7 units on a scale
Standard Deviation 18.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C2D1 (n=155, 133)
|
15.2 units on a scale
Standard Deviation 20.9
|
12.7 units on a scale
Standard Deviation 19.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C3D1 (n=154, 106)
|
13.9 units on a scale
Standard Deviation 21.2
|
9.9 units on a scale
Standard Deviation 16.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C4D1 (n=135, 91)
|
9.9 units on a scale
Standard Deviation 18.1
|
8.1 units on a scale
Standard Deviation 14.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C5D1 (n=123, 74)
|
9.2 units on a scale
Standard Deviation 14.7
|
9.0 units on a scale
Standard Deviation 16.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C6D1 (n=120, 70)
|
10.1 units on a scale
Standard Deviation 15.2
|
6.9 units on a scale
Standard Deviation 13.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C7D1 (n=115, 52)
|
7.1 units on a scale
Standard Deviation 11.9
|
7.7 units on a scale
Standard Deviation 11.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C8D1 (n=111, 43)
|
8.8 units on a scale
Standard Deviation 13.7
|
8.9 units on a scale
Standard Deviation 14.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C9D1 (n=101, 37)
|
6.9 units on a scale
Standard Deviation 13.0
|
9.5 units on a scale
Standard Deviation 19.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C10D1 (n=94, 33)
|
8.5 units on a scale
Standard Deviation 14.6
|
8.1 units on a scale
Standard Deviation 15.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C11D1 (n=84, 25)
|
8.3 units on a scale
Standard Deviation 12.8
|
8.0 units on a scale
Standard Deviation 16.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C12D1 (n=76, 23)
|
6.4 units on a scale
Standard Deviation 12.8
|
7.2 units on a scale
Standard Deviation 15.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C13D1 (n=74, 21)
|
8.6 units on a scale
Standard Deviation 14.1
|
7.1 units on a scale
Standard Deviation 16.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C14D1 (n=66, 19)
|
5.8 units on a scale
Standard Deviation 13.9
|
7.0 units on a scale
Standard Deviation 14.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C15D1 (n=62, 16)
|
5.9 units on a scale
Standard Deviation 11.3
|
6.2 units on a scale
Standard Deviation 13.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C16D1 (n=53, 12)
|
5.3 units on a scale
Standard Deviation 9.7
|
6.9 units on a scale
Standard Deviation 11.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C17D1 (n=47, 11)
|
7.8 units on a scale
Standard Deviation 12.5
|
10.6 units on a scale
Standard Deviation 11.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C18D1 (n=45, 11)
|
7.0 units on a scale
Standard Deviation 13.5
|
3.0 units on a scale
Standard Deviation 6.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C19D1 (n=40, 9)
|
8.8 units on a scale
Standard Deviation 14.6
|
9.3 units on a scale
Standard Deviation 12.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C20D1 (n=35, 8)
|
7.4 units on a scale
Standard Deviation 13.5
|
10.4 units on a scale
Standard Deviation 15.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C21D1 (n=30, 8)
|
7.8 units on a scale
Standard Deviation 12.9
|
8.3 units on a scale
Standard Deviation 12.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C22D1 (n=24, 7)
|
2.8 units on a scale
Standard Deviation 6.3
|
14.3 units on a scale
Standard Deviation 17.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C23D1 (n=23, 4)
|
5.4 units on a scale
Standard Deviation 10.5
|
45.8 units on a scale
Standard Deviation 21.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C24D1 (n=20, 3)
|
7.5 units on a scale
Standard Deviation 14.8
|
33.3 units on a scale
Standard Deviation 28.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C25D1 (n=18, 3)
|
3.7 units on a scale
Standard Deviation 9.1
|
27.8 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C26D1 (n=14, 3)
|
10.7 units on a scale
Standard Deviation 27.4
|
33.3 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C27D1 (n=14, 2)
|
11.9 units on a scale
Standard Deviation 27.3
|
33.3 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C28D1 (n=11, 2)
|
3.0 units on a scale
Standard Deviation 6.7
|
25.0 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C29D1 (n=8, 2)
|
10.4 units on a scale
Standard Deviation 15.3
|
25.0 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C30D1 (n=8, 1)
|
6.3 units on a scale
Standard Deviation 12.4
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C31D1 (n=7, 0)
|
14.3 units on a scale
Standard Deviation 17.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C32D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C34D1 (n=5, 0)
|
13.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C35D1 (n=4, 0)
|
12.5 units on a scale
Standard Deviation 16.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: Baseline (n=165, 163)
|
23.9 units on a scale
Standard Deviation 24.7
|
28.0 units on a scale
Standard Deviation 27.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C2D1 (n=155, 133)
|
13.9 units on a scale
Standard Deviation 19.8
|
25.7 units on a scale
Standard Deviation 25.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C3D1 (n=154, 106)
|
13.7 units on a scale
Standard Deviation 20.4
|
23.3 units on a scale
Standard Deviation 26.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C4D1 (n=135, 91)
|
13.0 units on a scale
Standard Deviation 19.5
|
19.0 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C5D1 (n=123, 74)
|
11.5 units on a scale
Standard Deviation 16.7
|
20.5 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C6D1 (n=120, 70)
|
10.6 units on a scale
Standard Deviation 15.0
|
19.5 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C7D1 (n=115, 52)
|
9.6 units on a scale
Standard Deviation 14.3
|
21.5 units on a scale
Standard Deviation 24.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C8D1 (n=111, 43)
|
11.3 units on a scale
Standard Deviation 18.0
|
17.4 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C9D1 (n=101, 37)
|
11.8 units on a scale
Standard Deviation 18.8
|
23.0 units on a scale
Standard Deviation 27.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C10D1 (n=94, 33)
|
8.7 units on a scale
Standard Deviation 14.0
|
24.2 units on a scale
Standard Deviation 28.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C11D1 (n=84, 25)
|
10.5 units on a scale
Standard Deviation 16.3
|
22.0 units on a scale
Standard Deviation 27.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C12D1 (n=76, 23)
|
8.6 units on a scale
Standard Deviation 14.3
|
25.4 units on a scale
Standard Deviation 29.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C13D1 (n=74, 21)
|
10.1 units on a scale
Standard Deviation 15.3
|
27.8 units on a scale
Standard Deviation 30.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C14D1 (n=66, 19)
|
8.1 units on a scale
Standard Deviation 12.8
|
23.7 units on a scale
Standard Deviation 26.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C15D1 (n=62, 16)
|
9.4 units on a scale
Standard Deviation 15.6
|
22.9 units on a scale
Standard Deviation 25.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C16D1 (n=53, 12)
|
9.4 units on a scale
Standard Deviation 14.4
|
31.9 units on a scale
Standard Deviation 28.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C17D1 (n=47, 11)
|
10.6 units on a scale
Standard Deviation 16.1
|
24.2 units on a scale
Standard Deviation 27.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C18D1 (n=45, 11)
|
11.1 units on a scale
Standard Deviation 18.1
|
24.2 units on a scale
Standard Deviation 29.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C19D1 (n=40, 9)
|
11.3 units on a scale
Standard Deviation 17.0
|
24.1 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C20D1 (n=35, 8)
|
11.9 units on a scale
Standard Deviation 18.8
|
22.9 units on a scale
Standard Deviation 28.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C21D1 (n=30, 8)
|
11.7 units on a scale
Standard Deviation 15.3
|
29.2 units on a scale
Standard Deviation 30.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C22D1 (n=24, 7)
|
6.9 units on a scale
Standard Deviation 12.9
|
33.3 units on a scale
Standard Deviation 28.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C23D1 (n=23, 4)
|
9.1 units on a scale
Standard Deviation 16.1
|
33.3 units on a scale
Standard Deviation 36.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C24D1 (n=20, 3)
|
4.2 units on a scale
Standard Deviation 11.9
|
27.8 units on a scale
Standard Deviation 48.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C25D1 (n=18, 3)
|
4.6 units on a scale
Standard Deviation 7.7
|
38.9 units on a scale
Standard Deviation 41.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C26D1 (n=14, 3)
|
17.9 units on a scale
Standard Deviation 27.3
|
38.9 units on a scale
Standard Deviation 41.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C27D1 (n=14, 2)
|
13.1 units on a scale
Standard Deviation 25.5
|
58.3 units on a scale
Standard Deviation 35.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C28D1 (n=11, 2)
|
4.5 units on a scale
Standard Deviation 7.8
|
50.0 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C29D1 (n=8, 2)
|
2.1 units on a scale
Standard Deviation 5.9
|
41.7 units on a scale
Standard Deviation 35.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C30D1 (n=8, 1)
|
4.2 units on a scale
Standard Deviation 7.7
|
83.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C31D1 (n=7, 0)
|
4.8 units on a scale
Standard Deviation 8.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C32D1 (n=6, 0)
|
5.6 units on a scale
Standard Deviation 8.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C33D1 (n=6, 0)
|
2.8 units on a scale
Standard Deviation 6.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C34D1 (n=5, 0)
|
3.3 units on a scale
Standard Deviation 7.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C35D1 (n=4, 0)
|
8.3 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: Baseline (n=165, 163)
|
31.1 units on a scale
Standard Deviation 28.3
|
32.5 units on a scale
Standard Deviation 28.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C2D1 (n=155, 133)
|
21.5 units on a scale
Standard Deviation 21.4
|
33.6 units on a scale
Standard Deviation 27.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C3D1 (n=154, 106)
|
21.6 units on a scale
Standard Deviation 23.0
|
33.3 units on a scale
Standard Deviation 28.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C4D1 (n=135, 91)
|
17.3 units on a scale
Standard Deviation 20.7
|
29.3 units on a scale
Standard Deviation 26.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C5D1 (n=123, 74)
|
16.0 units on a scale
Standard Deviation 20.6
|
29.3 units on a scale
Standard Deviation 24.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C6D1 (n=120, 70)
|
15.8 units on a scale
Standard Deviation 22.0
|
26.2 units on a scale
Standard Deviation 24.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C7D1 (n=115, 52)
|
17.4 units on a scale
Standard Deviation 20.9
|
28.2 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C8D1 (n=111, 43)
|
15.8 units on a scale
Standard Deviation 19.7
|
22.5 units on a scale
Standard Deviation 28.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C9D1 (n=101, 37)
|
13.9 units on a scale
Standard Deviation 19.0
|
23.4 units on a scale
Standard Deviation 24.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C10D1 (n=94, 33)
|
17.7 units on a scale
Standard Deviation 20.6
|
24.2 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C11D1 (n=84, 25)
|
17.5 units on a scale
Standard Deviation 22.8
|
25.3 units on a scale
Standard Deviation 22.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C12D1 (n=76, 23)
|
14.5 units on a scale
Standard Deviation 19.9
|
30.4 units on a scale
Standard Deviation 28.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C13D1 (n=74, 21)
|
14.0 units on a scale
Standard Deviation 20.6
|
23.8 units on a scale
Standard Deviation 23.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C14D1 (n=66, 19)
|
15.2 units on a scale
Standard Deviation 21.2
|
29.8 units on a scale
Standard Deviation 24.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C15D1 (n=62, 16)
|
15.6 units on a scale
Standard Deviation 21.5
|
20.8 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C21D1 (n=30, 8)
|
13.3 units on a scale
Standard Deviation 16.6
|
33.3 units on a scale
Standard Deviation 17.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C22D1 (n=24, 7)
|
13.9 units on a scale
Standard Deviation 19.5
|
28.6 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C23D1 (n=23, 4)
|
9.4 units on a scale
Standard Deviation 14.9
|
41.7 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C24D1 (n=20, 3)
|
18.3 units on a scale
Standard Deviation 20.2
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C25D1 (n=18, 3)
|
11.1 units on a scale
Standard Deviation 16.2
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C26D1 (n=14, 3)
|
14.3 units on a scale
Standard Deviation 28.4
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C27D1 (n=14, 2)
|
11.9 units on a scale
Standard Deviation 16.6
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C28D1 (n=11, 2)
|
12.1 units on a scale
Standard Deviation 16.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C29D1 (n=8, 2)
|
4.2 units on a scale
Standard Deviation 11.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C30D1 (n=8, 1)
|
8.3 units on a scale
Standard Deviation 15.4
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 16.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C32D1 (n=6, 0)
|
16.7 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C34D1 (n=5, 0)
|
13.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C35D1 (n=4, 0)
|
16.7 units on a scale
Standard Deviation 19.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : Baseline (n=164, 163)
|
22.6 units on a scale
Standard Deviation 26.4
|
27.8 units on a scale
Standard Deviation 27.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C2D1 (n=155, 133)
|
15.3 units on a scale
Standard Deviation 23.5
|
27.1 units on a scale
Standard Deviation 25.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C3D1 (n=154, 106)
|
16.2 units on a scale
Standard Deviation 26.2
|
23.6 units on a scale
Standard Deviation 26.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C4D1 (n=135, 91)
|
13.3 units on a scale
Standard Deviation 21.2
|
23.8 units on a scale
Standard Deviation 26.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C5D1 (n=123, 74)
|
13.6 units on a scale
Standard Deviation 21.3
|
25.7 units on a scale
Standard Deviation 26.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C6D1 (n=120, 70)
|
14.2 units on a scale
Standard Deviation 21.9
|
23.3 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C7D1 (n=114, 52)
|
9.4 units on a scale
Standard Deviation 17.5
|
21.8 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C8D1 (n=111, 43)
|
12.5 units on a scale
Standard Deviation 21.5
|
21.7 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C9D1 (n=100, 37)
|
12.3 units on a scale
Standard Deviation 21.5
|
22.5 units on a scale
Standard Deviation 24.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C10D1 (n=94, 33)
|
13.5 units on a scale
Standard Deviation 23.6
|
24.2 units on a scale
Standard Deviation 25.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C11D1 (n=84, 25)
|
13.9 units on a scale
Standard Deviation 22.1
|
22.7 units on a scale
Standard Deviation 24.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C12D1 (n=76, 23)
|
13.6 units on a scale
Standard Deviation 21.9
|
23.2 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C13D1 (n=74, 21)
|
10.8 units on a scale
Standard Deviation 19.2
|
25.4 units on a scale
Standard Deviation 25.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C14D1 (n=66, 19)
|
11.1 units on a scale
Standard Deviation 18.8
|
24.6 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C15D1 (n=62, 16)
|
11.3 units on a scale
Standard Deviation 20.0
|
29.2 units on a scale
Standard Deviation 26.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C16D1 (n=53, 11)
|
13.8 units on a scale
Standard Deviation 20.1
|
21.2 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C17D1 (n=47, 11)
|
13.5 units on a scale
Standard Deviation 21.6
|
15.2 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C18D1 (n=45, 11)
|
12.6 units on a scale
Standard Deviation 17.8
|
21.2 units on a scale
Standard Deviation 27.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C19D1 (n=40, 9)
|
13.3 units on a scale
Standard Deviation 19.7
|
22.2 units on a scale
Standard Deviation 28.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C20D1 (n=35, 8)
|
15.2 units on a scale
Standard Deviation 20.4
|
20.8 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C21D1 (n=30, 8)
|
12.2 units on a scale
Standard Deviation 18.5
|
29.2 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C22D1 (n=24, 7)
|
12.5 units on a scale
Standard Deviation 19.2
|
31.0 units on a scale
Standard Deviation 24.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C23D1 (n=23, 4)
|
17.4 units on a scale
Standard Deviation 26.3
|
50.0 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C24D1 (n=20, 3)
|
11.7 units on a scale
Standard Deviation 22.4
|
22.2 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C25D1 (n=18, 3)
|
20.4 units on a scale
Standard Deviation 30.5
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C26D1 (n=14, 3)
|
21.4 units on a scale
Standard Deviation 33.6
|
22.2 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C27D1 (n=14, 2)
|
16.7 units on a scale
Standard Deviation 21.7
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C28D1 (n=11, 2)
|
9.1 units on a scale
Standard Deviation 15.6
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C29D1 (n=8, 2)
|
8.3 units on a scale
Standard Deviation 15.4
|
33.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C30D1 (n=8, 1)
|
12.5 units on a scale
Standard Deviation 24.8
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C31D1 (n=7, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C32D1 (n=6, 0)
|
5.6 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C33D1 (n=6, 0)
|
5.6 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C34D1 (n=5, 0)
|
13.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C35D1 (n=4, 0)
|
16.7 units on a scale
Standard Deviation 19.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia : C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : Baseline(n=165, 163)
|
24.4 units on a scale
Standard Deviation 28.8
|
23.3 units on a scale
Standard Deviation 28.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C2/D1(n=155, 133)
|
21.1 units on a scale
Standard Deviation 30.2
|
24.3 units on a scale
Standard Deviation 28.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C3/D1(n=154, 106)
|
18.4 units on a scale
Standard Deviation 29.0
|
21.7 units on a scale
Standard Deviation 27.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C4/D1(n=135, 91)
|
14.6 units on a scale
Standard Deviation 24.3
|
19.4 units on a scale
Standard Deviation 23.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C5/D1(n=123, 74)
|
12.7 units on a scale
Standard Deviation 22.4
|
19.4 units on a scale
Standard Deviation 28.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C6/D1(n=120, 70)
|
13.6 units on a scale
Standard Deviation 21.8
|
12.9 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C7/D1(n=115, 52)
|
10.4 units on a scale
Standard Deviation 19.4
|
12.8 units on a scale
Standard Deviation 22.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C8/D1(n=111, 43)
|
12.8 units on a scale
Standard Deviation 20.8
|
10.9 units on a scale
Standard Deviation 22.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C9/D1(n=101, 37)
|
12.2 units on a scale
Standard Deviation 239
|
14.4 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C10/D1(n=94, 33)
|
12.4 units on a scale
Standard Deviation 22.9
|
14.1 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C11/D1(n=84, 25)
|
13.5 units on a scale
Standard Deviation 19.4
|
14.7 units on a scale
Standard Deviation 25.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C12/D1(n=76, 23)
|
11.0 units on a scale
Standard Deviation 21.4
|
14.5 units on a scale
Standard Deviation 24.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C13/D1(n=74, 21)
|
9.5 units on a scale
Standard Deviation 20.3
|
17.5 units on a scale
Standard Deviation 27.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C15/D1(n=62, 16)
|
8.6 units on a scale
Standard Deviation 20.9
|
12.5 units on a scale
Standard Deviation 26.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C16/D1(n=53, 12)
|
8.8 units on a scale
Standard Deviation 18.7
|
16.7 units on a scale
Standard Deviation 30.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C17/D1(n=47, 11)
|
8.5 units on a scale
Standard Deviation 16.3
|
15.2 units on a scale
Standard Deviation 31.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C18/D1(n=45, 11)
|
11.1 units on a scale
Standard Deviation 17.4
|
12.1 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C19/D1(n=40, 9)
|
8.3 units on a scale
Standard Deviation 16.5
|
18.5 units on a scale
Standard Deviation 33.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C20/D1(n=35, 8)
|
7.6 units on a scale
Standard Deviation 16.3
|
20.8 units on a scale
Standard Deviation 35.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C21/D1(n=30, 8)
|
11.1 units on a scale
Standard Deviation 16.0
|
25.0 units on a scale
Standard Deviation 34.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C22/D1(n=24, 7)
|
6.9 units on a scale
Standard Deviation 13.8
|
14.3 units on a scale
Standard Deviation 37.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C23/D1(n=23, 4)
|
9.4 units on a scale
Standard Deviation 14.9
|
50.0 units on a scale
Standard Deviation 43.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C24/D1(n=20, 3)
|
5.0 units on a scale
Standard Deviation 12.2
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C25/D1(n=18, 3)
|
1.9 units on a scale
Standard Deviation 7.9
|
44.4 units on a scale
Standard Deviation 50.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C26/D1(n=14, 3)
|
11.9 units on a scale
Standard Deviation 21.1
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C27/D1(n=14, 2)
|
7.1 units on a scale
Standard Deviation 19.3
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C28/D1(n=11, 2)
|
15.2 units on a scale
Standard Deviation 17.4
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C29/D1(n=8, 2)
|
12.5 units on a scale
Standard Deviation 17.3
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C30/D1(n=8, 1)
|
8.3 units on a scale
Standard Deviation 15.4
|
100.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss : C31/D1(n=7, 0)
|
14.3 units on a scale
Standard Deviation 17.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: Baseline (n=164, 162)
|
14.8 units on a scale
Standard Deviation 25.1
|
16.9 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C2D1 (n=155, 133)
|
28.6 units on a scale
Standard Deviation 30.5
|
14.0 units on a scale
Standard Deviation 24.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C3D1 (n=154, 106)
|
27.1 units on a scale
Standard Deviation 30.0
|
16.0 units on a scale
Standard Deviation 22.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C4D1 (n=134, 90)
|
22.9 units on a scale
Standard Deviation 26.6
|
14.8 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C5D1 (n=123, 74)
|
21.4 units on a scale
Standard Deviation 25.7
|
20.3 units on a scale
Standard Deviation 29.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C6D1 (n=120, 70)
|
21.7 units on a scale
Standard Deviation 23.9
|
15.7 units on a scale
Standard Deviation 23.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C7D1 (n=115, 52)
|
21.7 units on a scale
Standard Deviation 26.1
|
19.9 units on a scale
Standard Deviation 26.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C8D1 (n=111, 43)
|
18.6 units on a scale
Standard Deviation 24.1
|
16.3 units on a scale
Standard Deviation 24.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C9D1 (n=101, 37)
|
18.8 units on a scale
Standard Deviation 22.3
|
16.2 units on a scale
Standard Deviation 21.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C10D1 (n=94, 33)
|
16.0 units on a scale
Standard Deviation 22.8
|
19.2 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C11D1 (n=84, 25)
|
21.0 units on a scale
Standard Deviation 25.8
|
21.3 units on a scale
Standard Deviation 19.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C12D1 (n=76, 23)
|
19.7 units on a scale
Standard Deviation 24.5
|
21.7 units on a scale
Standard Deviation 23.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C13D1 (n=74, 21)
|
21.2 units on a scale
Standard Deviation 26.2
|
22.2 units on a scale
Standard Deviation 26.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C14D1 (n=66, 19)
|
21.7 units on a scale
Standard Deviation 27.1
|
24.6 units on a scale
Standard Deviation 31.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C15D1 (n=62, 16)
|
22.6 units on a scale
Standard Deviation 27.5
|
18.7 units on a scale
Standard Deviation 21.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C16D1 (n=53, 12)
|
19.5 units on a scale
Standard Deviation 26.5
|
22.2 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C17D1 (n=47, 11)
|
22.0 units on a scale
Standard Deviation 27.2
|
24.2 units on a scale
Standard Deviation 30.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C18D1 (n=44, 11)
|
22.7 units on a scale
Standard Deviation 25.7
|
15.2 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C19D1 (n=40, 9)
|
25.0 units on a scale
Standard Deviation 25.9
|
22.2 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C20D1 (n=35, 8)
|
22.9 units on a scale
Standard Deviation 26.5
|
20.8 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C21D1 (n=30, 8)
|
24.4 units on a scale
Standard Deviation 28.9
|
16.7 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C22D1 (n=24, 7)
|
18.1 units on a scale
Standard Deviation 24.0
|
19.0 units on a scale
Standard Deviation 26.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C23D1 (n=23, 4)
|
11.6 units on a scale
Standard Deviation 19.1
|
25.0 units on a scale
Standard Deviation 31.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C24D1 (n=20, 3)
|
21.7 units on a scale
Standard Deviation 24.8
|
22.2 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C25D1 (n=18, 3)
|
22.2 units on a scale
Standard Deviation 32.3
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C26D1 (n=14, 3)
|
26.2 units on a scale
Standard Deviation 32.5
|
44.4 units on a scale
Standard Deviation 50.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C27D1 (n=14, 2)
|
35.7 units on a scale
Standard Deviation 40.2
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C29D1 (n=8, 2)
|
29.2 units on a scale
Standard Deviation 21.4
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C30D1 (n=8, 1)
|
29.2 units on a scale
Standard Deviation 27.8
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C31D1 (n=7, 0)
|
33.3 units on a scale
Standard Deviation 27.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C32D1 (n=6, 0)
|
33.3 units on a scale
Standard Deviation 42.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C33D1 (n=6, 0)
|
38.9 units on a scale
Standard Deviation 25.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C34D1 (n=5, 0)
|
40.0 units on a scale
Standard Deviation 43.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C35D1 (n=4, 0)
|
33.3 units on a scale
Standard Deviation 27.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Constipation: EOT (n=49, 90)
|
28.6 units on a scale
Standard Deviation 27.2
|
18.1 units on a scale
Standard Deviation 25.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: Baseline (n=165, 162)
|
9.7 units on a scale
Standard Deviation 19.1
|
7.8 units on a scale
Standard Deviation 16.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C2D1 (n=155, 132)
|
18.1 units on a scale
Standard Deviation 26.7
|
11.1 units on a scale
Standard Deviation 20.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C3D1 (n=153, 106)
|
21.6 units on a scale
Standard Deviation 28.7
|
7.9 units on a scale
Standard Deviation 18.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C4D1 (n=134, 90)
|
23.1 units on a scale
Standard Deviation 26.9
|
8.5 units on a scale
Standard Deviation 18.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C5D1 (n=123, 74)
|
24.4 units on a scale
Standard Deviation 25.6
|
5.9 units on a scale
Standard Deviation 15.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C6D1 (n=120, 70)
|
22.2 units on a scale
Standard Deviation 26.4
|
7.1 units on a scale
Standard Deviation 16.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C7D1 (n=115, 52)
|
20.6 units on a scale
Standard Deviation 24.8
|
9.6 units on a scale
Standard Deviation 16.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C8D1 (n=111, 43)
|
18.6 units on a scale
Standard Deviation 24.1
|
9.3 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C9D1 (n=101, 37)
|
17.3 units on a scale
Standard Deviation 22.8
|
7.2 units on a scale
Standard Deviation 16.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C10D1 (n=94, 33)
|
17.7 units on a scale
Standard Deviation 22.3
|
7.1 units on a scale
Standard Deviation 16.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C11D1 (n=84, 25)
|
21.0 units on a scale
Standard Deviation 22.4
|
8.0 units on a scale
Standard Deviation 17.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C12D1 (n=76, 23)
|
17.5 units on a scale
Standard Deviation 25.2
|
8.7 units on a scale
Standard Deviation 15.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C13D1 (n=74, 21)
|
17.6 units on a scale
Standard Deviation 23.6
|
12.7 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C14D1 (n=66, 19)
|
17.7 units on a scale
Standard Deviation 22.8
|
8.8 units on a scale
Standard Deviation 18.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C15D1 (n=62, 16)
|
16.1 units on a scale
Standard Deviation 21.5
|
4.2 units on a scale
Standard Deviation 11.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C16D1 (n=52, 12)
|
16.0 units on a scale
Standard Deviation 20.3
|
5.6 units on a scale
Standard Deviation 13.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C17D1 (n=47, 11)
|
19.9 units on a scale
Standard Deviation 22.7
|
12.1 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C18D1 (n=44, 11)
|
22.7 units on a scale
Standard Deviation 25.7
|
12.1 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C19D1 (n=40, 9)
|
21.7 units on a scale
Standard Deviation 25.7
|
7.4 units on a scale
Standard Deviation 14.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C20D1 (n=35, 8)
|
21.0 units on a scale
Standard Deviation 24.4
|
4.2 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C21D1 (n=30, 8)
|
22.2 units on a scale
Standard Deviation 22.0
|
8.3 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C22D1 (n=24, 7)
|
23.6 units on a scale
Standard Deviation 25.0
|
11.9 units on a scale
Standard Deviation 15.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C23D1 (n=23, 4)
|
15.9 units on a scale
Standard Deviation 19.8
|
25.0 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C24D1 (n=20, 3)
|
21.7 units on a scale
Standard Deviation 22.4
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C25D1 (n=18, 3)
|
20.4 units on a scale
Standard Deviation 25.9
|
22.2 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C26D1 (n=14, 3)
|
19.0 units on a scale
Standard Deviation 25.2
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C27D1 (n=14, 2)
|
23.8 units on a scale
Standard Deviation 30.5
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C28D1 (n=11, 2)
|
15.2 units on a scale
Standard Deviation 17.4
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C29D1 (n=8, 2)
|
20.8 units on a scale
Standard Deviation 24.8
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C30D1 (n=8, 1)
|
12.5 units on a scale
Standard Deviation 17.3
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C31D1 (n=7, 0)
|
14.3 units on a scale
Standard Deviation 17.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C32D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C34D1 (n=5, 0)
|
6.7 units on a scale
Standard Deviation 14.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C35D1 (n=4, 0)
|
16.7 units on a scale
Standard Deviation 19.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C36D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: C37D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Diarrhea: EOT (n=49, 90)
|
18.4 units on a scale
Standard Deviation 23.6
|
10.0 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: Baseline (n=165, 161)
|
28.5 units on a scale
Standard Deviation 33.0
|
27.3 units on a scale
Standard Deviation 30.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C2D1 (n=155, 133)
|
21.9 units on a scale
Standard Deviation 27.2
|
22.3 units on a scale
Standard Deviation 28.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C3D1 (n=154, 105)
|
19.0 units on a scale
Standard Deviation 26.6
|
20.3 units on a scale
Standard Deviation 27.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C4D1 (n=135, 90)
|
17.5 units on a scale
Standard Deviation 26.0
|
21.9 units on a scale
Standard Deviation 26.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C5D1 (n=123, 74)
|
16.8 units on a scale
Standard Deviation 25.0
|
19.4 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C6D1 (n=120, 70)
|
15.6 units on a scale
Standard Deviation 24.0
|
18.6 units on a scale
Standard Deviation 25.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C7D1 (n=115, 52)
|
14.8 units on a scale
Standard Deviation 21.3
|
18.6 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C8D1 (n=111, 43)
|
16.8 units on a scale
Standard Deviation 25.0
|
15.5 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C9D1 (n=101, 36)
|
17.8 units on a scale
Standard Deviation 26.1
|
16.7 units on a scale
Standard Deviation 23.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C10D1 (n=94, 33)
|
16.3 units on a scale
Standard Deviation 26.2
|
15.2 units on a scale
Standard Deviation 23.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C11D1 (n=84, 25)
|
17.5 units on a scale
Standard Deviation 25.1
|
17.3 units on a scale
Standard Deviation 21.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C12D1 (n=76, 23)
|
17.1 units on a scale
Standard Deviation 24.6
|
18.8 units on a scale
Standard Deviation 28.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C13D1 (n=74, 21)
|
16.2 units on a scale
Standard Deviation 24.2
|
17.5 units on a scale
Standard Deviation 27.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C14D1 (n=66, 19)
|
14.1 units on a scale
Standard Deviation 20.3
|
17.5 units on a scale
Standard Deviation 32.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C15D1 (n=62, 16)
|
14.0 units on a scale
Standard Deviation 23.0
|
16.7 units on a scale
Standard Deviation 27.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C16D1 (n=53, 12)
|
15.7 units on a scale
Standard Deviation 25.0
|
30.6 units on a scale
Standard Deviation 36.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C17D1 (n=47, 11)
|
17.7 units on a scale
Standard Deviation 29.4
|
33.3 units on a scale
Standard Deviation 36.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C18D1 (n=44, 11)
|
18.9 units on a scale
Standard Deviation 30.0
|
15.2 units on a scale
Standard Deviation 31.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C19D1 (n=40, 9)
|
17.5 units on a scale
Standard Deviation 31.1
|
25.9 units on a scale
Standard Deviation 32.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C20D1 (n=35, 8)
|
16.2 units on a scale
Standard Deviation 27.3
|
25.0 units on a scale
Standard Deviation 34.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C21D1 (n=30, 8)
|
13.3 units on a scale
Standard Deviation 27.1
|
29.2 units on a scale
Standard Deviation 33.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C22D1 (n=24, 7)
|
18.1 units on a scale
Standard Deviation 31.1
|
28.6 units on a scale
Standard Deviation 35.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C23D1 (n=23, 4)
|
17.4 units on a scale
Standard Deviation 31.6
|
33.3 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C24D1 (n=20, 3)
|
20.0 units on a scale
Standard Deviation 33.2
|
33.3 units on a scale
Standard Deviation 57.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C25D1 (n=18, 3)
|
11.1 units on a scale
Standard Deviation 16.2
|
44.4 units on a scale
Standard Deviation 50.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C26D1 (n=14, 3)
|
14.3 units on a scale
Standard Deviation 17.1
|
44.4 units on a scale
Standard Deviation 50.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C27D1 (n=14, 2)
|
14.3 units on a scale
Standard Deviation 17.1
|
66.7 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C28D1 (n=11, 2)
|
15.2 units on a scale
Standard Deviation 22.9
|
66.7 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C29D1 (n=8, 2)
|
8.3 units on a scale
Standard Deviation 15.4
|
66.7 units on a scale
Standard Deviation 47.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C30D1 (n=8, 1)
|
4.2 units on a scale
Standard Deviation 11.8
|
100.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 16.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C32D1 (n=6, 0)
|
22.2 units on a scale
Standard Deviation 27.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C33D1 (n=6, 0)
|
16.7 units on a scale
Standard Deviation 27.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C34D1 (n=5, 0)
|
13.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C35D1 (n=4, 0)
|
8.3 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C36D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: C37D1 (n=1, 0)
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Financial Difficulties: EOT (n=49, 90)
|
17.0 units on a scale
Standard Deviation 27.3
|
24.1 units on a scale
Standard Deviation 30.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C32D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C34D1 (n=5, 0)
|
13.3 units on a scale
Standard Deviation 18.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C35D1 (n=4, 0)
|
16.7 units on a scale
Standard Deviation 19.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Appetite loss: EOT (n=49, 90)
|
21.8 units on a scale
Standard Deviation 26.0
|
28.1 units on a scale
Standard Deviation 30.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global Qol: EOT (n=49, 90)
|
56.1 units on a scale
Standard Deviation 24.5
|
46.4 units on a scale
Standard Deviation 25.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Physical Functioning: EOT (n=49, 90)
|
80.7 units on a scale
Standard Deviation 23.0
|
66.2 units on a scale
Standard Deviation 27.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Role Functioning: EOT (n=49, 90)
|
71.8 units on a scale
Standard Deviation 27.7
|
54.1 units on a scale
Standard Deviation 34.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Emotional Functioning: EOT (n=49, 90)
|
75.2 units on a scale
Standard Deviation 25.1
|
74.5 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Cognitive Functioning: EOT (n=49, 90)
|
83.7 units on a scale
Standard Deviation 20.3
|
80.0 units on a scale
Standard Deviation 24.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Social Function: EOT (n=49, 90)
|
78.2 units on a scale
Standard Deviation 27.9
|
59.4 units on a scale
Standard Deviation 33.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Fatigue: EOT (n=49, 90)
|
32.0 units on a scale
Standard Deviation 28.2
|
46.9 units on a scale
Standard Deviation 26.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Nausea and Vomiting: EOT (n=49, 90)
|
16.3 units on a scale
Standard Deviation 22.9
|
15.7 units on a scale
Standard Deviation 20.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Pain: EOT (n=49, 90)
|
23.8 units on a scale
Standard Deviation 30.4
|
33.7 units on a scale
Standard Deviation 31.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Dyspnea: EOT (n=49, 90)
|
23.8 units on a scale
Standard Deviation 28.1
|
40.0 units on a scale
Standard Deviation 30.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Insomnia: EOT (n=49, 90)
|
18.4 units on a scale
Standard Deviation 24.6
|
30.4 units on a scale
Standard Deviation 27.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: Baseline (n=165, 162)
|
57.2 units on a scale
Standard Deviation 21.5
|
58.1 units on a scale
Standard Deviation 22.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C2D1 (n=154, 133)
|
64.5 units on a scale
Standard Deviation 21.8
|
58.1 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C3D1 (n=154, 106)
|
65.2 units on a scale
Standard Deviation 22.1
|
59.4 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C4D1 (n=135, 90)
|
68.4 units on a scale
Standard Deviation 19.6
|
61.1 units on a scale
Standard Deviation 20.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C5D1 (n=123, 74)
|
68.5 units on a scale
Standard Deviation 20.2
|
64.1 units on a scale
Standard Deviation 22.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C6D1 (n=120, 70)
|
68.3 units on a scale
Standard Deviation 19.8
|
67.5 units on a scale
Standard Deviation 23.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C7D1 (n=114, 52)
|
69.5 units on a scale
Standard Deviation 19.3
|
66.5 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C8D1 (n=110, 43)
|
68.7 units on a scale
Standard Deviation 20.1
|
66.9 units on a scale
Standard Deviation 25.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C9D1 (n=101, 37)
|
68.7 units on a scale
Standard Deviation 21.0
|
66.4 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C10D1 (n=94, 33)
|
67.0 units on a scale
Standard Deviation 21.6
|
67.4 units on a scale
Standard Deviation 26.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C11D1 (n=83, 25)
|
69.5 units on a scale
Standard Deviation 20.2
|
71.0 units on a scale
Standard Deviation 21.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C12D1 (n=76, 23)
|
67.9 units on a scale
Standard Deviation 22.0
|
65.6 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C13D1 (n=74, 21)
|
66.8 units on a scale
Standard Deviation 23.6
|
66.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Global QoL: C14D1 (n=66, 19)
|
71.5 units on a scale
Standard Deviation 20.0
|
65.8 units on a scale
Standard Deviation 23.4
|
SECONDARY outcome
Timeframe: Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks)Population: FAS included all participants who were randomized to study treatment. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for specified time points for each arm group, respectively.
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: 1 'Not at All' to 4 'Very Much'. Scores averaged, transformed to 0-100 scale; higher symptom score = greater degree of symptoms.
Outcome measures
| Measure |
Crizotinib
n=164 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=162 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C34D1 (n=5, 0)
|
20.0 units on a scale
Standard Deviation 44.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C28D1 (n=11, 2)
|
9.1 units on a scale
Standard Deviation 15.6
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C30D1 (n=8, 1)
|
0.0 units on a scale
Standard Deviation 0.0
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C30D1 (n=8, 1)
|
12.5 units on a scale
Standard Deviation 35.4
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 25.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C32D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C34D1 (n=5, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C35D1 (n=4, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: EOT (n=49, 90)
|
6.8 units on a scale
Standard Deviation 18.0
|
33.3 units on a scale
Standard Deviation 37.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: Baseline (n=163, 160)
|
18.8 units on a scale
Standard Deviation 22.8
|
24.0 units on a scale
Standard Deviation 27.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C2D1 (n=155, 132)
|
9.5 units on a scale
Standard Deviation 17.7
|
23.7 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C3D1 (n=153, 106)
|
7.0 units on a scale
Standard Deviation 13.6
|
23.3 units on a scale
Standard Deviation 26.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C4D1 (n=135, 91)
|
7.4 units on a scale
Standard Deviation 13.9
|
19.8 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C5D1 (n=123, 74)
|
6.8 units on a scale
Standard Deviation 14.1
|
17.1 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C6D1 (n=119, 70)
|
6.2 units on a scale
Standard Deviation 13.0
|
16.2 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C7D1 (n=115, 52)
|
7.5 units on a scale
Standard Deviation 14.7
|
16.7 units on a scale
Standard Deviation 22.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C8D1 (n=111, 43)
|
5.1 units on a scale
Standard Deviation 14.4
|
14.0 units on a scale
Standard Deviation 20.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C9D1 (n=101, 37)
|
5.9 units on a scale
Standard Deviation 12.8
|
17.1 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C10D1 (n=94, 33)
|
6.7 units on a scale
Standard Deviation 14.3
|
18.2 units on a scale
Standard Deviation 31.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C11D1 (n=84, 25)
|
6.3 units on a scale
Standard Deviation 13.2
|
20.0 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C12D1 (n=76, 23)
|
5.3 units on a scale
Standard Deviation 12.2
|
23.2 units on a scale
Standard Deviation 30.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C13D1 (n=74, 21)
|
6.3 units on a scale
Standard Deviation 13.1
|
23.8 units on a scale
Standard Deviation 30.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C14D1 (n=66, 19)
|
7.6 units on a scale
Standard Deviation 16.3
|
22.8 units on a scale
Standard Deviation 22.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C15D1 (n=62, 16)
|
5.9 units on a scale
Standard Deviation 14.2
|
18.7 units on a scale
Standard Deviation 24.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C16D1 (n=53, 12)
|
3.8 units on a scale
Standard Deviation 10.7
|
16.7 units on a scale
Standard Deviation 17.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C17D1 (n=46, 11)
|
7.2 units on a scale
Standard Deviation 15.6
|
21.2 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C18D1 (n=45, 11)
|
5.9 units on a scale
Standard Deviation 16.3
|
24.2 units on a scale
Standard Deviation 33.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C19D1 (n=40, 9)
|
5.0 units on a scale
Standard Deviation 14.2
|
18.5 units on a scale
Standard Deviation 24.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C20D1 (n=35, 8)
|
5.7 units on a scale
Standard Deviation 15.1
|
29.2 units on a scale
Standard Deviation 21.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C21D1 (n=30, 8)
|
5.6 units on a scale
Standard Deviation 15.4
|
25.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C22D1 (n=24, 7)
|
4.2 units on a scale
Standard Deviation 11.3
|
26.2 units on a scale
Standard Deviation 30.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C23D1 (n=23, 4)
|
3.6 units on a scale
Standard Deviation 10.0
|
41.7 units on a scale
Standard Deviation 31.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C24D1 (n=20, 3)
|
1.7 units on a scale
Standard Deviation 7.5
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C25D1 (n=18, 3)
|
5.6 units on a scale
Standard Deviation 12.8
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C26D1 (n=14, 3)
|
7.1 units on a scale
Standard Deviation 19.3
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C27D1 (n=14, 2)
|
4.8 units on a scale
Standard Deviation 12.1
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C29D1 (n=8, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C30D1 (n=8, 1)
|
4.2 units on a scale
Standard Deviation 11.8
|
66.7 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 16.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C32D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C34D1 (n=5, 0)
|
6.7 units on a scale
Standard Deviation 14.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C35D1 (n=4, 0)
|
8.3 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Chest: EOT (n=49, 90)
|
17.0 units on a scale
Standard Deviation 24.6
|
28.5 units on a scale
Standard Deviation 29.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: Baseline (n=164, 161)
|
16.3 units on a scale
Standard Deviation 24.1
|
19.5 units on a scale
Standard Deviation 28.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C2D1 (n=155, 132)
|
9.0 units on a scale
Standard Deviation 18.3
|
19.9 units on a scale
Standard Deviation 27.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C3D1 (n=153, 105)
|
8.1 units on a scale
Standard Deviation 14.8
|
17.5 units on a scale
Standard Deviation 24.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C4D1 (n=135, 91)
|
6.9 units on a scale
Standard Deviation 15.3
|
14.3 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C5D1 (n=123, 74)
|
6.2 units on a scale
Standard Deviation 15.0
|
13.1 units on a scale
Standard Deviation 21.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C6D1 (n=119, 70)
|
6.7 units on a scale
Standard Deviation 14.1
|
17.1 units on a scale
Standard Deviation 25.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C7D1 (n=115, 52)
|
6.4 units on a scale
Standard Deviation 13.2
|
17.3 units on a scale
Standard Deviation 23.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C8D1 (n=111, 43)
|
6.9 units on a scale
Standard Deviation 14.3
|
20.2 units on a scale
Standard Deviation 28.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C9D1 (n=101, 37)
|
5.6 units on a scale
Standard Deviation 12.5
|
23.4 units on a scale
Standard Deviation 28.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C10D1 (n=94, 33)
|
7.4 units on a scale
Standard Deviation 17.0
|
25.3 units on a scale
Standard Deviation 32.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C11D1 (n=84, 25)
|
6.0 units on a scale
Standard Deviation 14.8
|
24.0 units on a scale
Standard Deviation 26.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C12D1 (n=76, 23)
|
6.6 units on a scale
Standard Deviation 15.4
|
29.0 units on a scale
Standard Deviation 35.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C13D1 (n=74, 21)
|
5.9 units on a scale
Standard Deviation 12.8
|
25.4 units on a scale
Standard Deviation 34.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C14D1 (n=66, 19)
|
7.6 units on a scale
Standard Deviation 18.3
|
29.8 units on a scale
Standard Deviation 31.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C15D1 (n=62, 16)
|
5.4 units on a scale
Standard Deviation 13.8
|
25.0 units on a scale
Standard Deviation 25.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C16D1 (n=53, 12)
|
5.0 units on a scale
Standard Deviation 12.0
|
16.7 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C17D1 (n=47, 11)
|
3.5 units on a scale
Standard Deviation 10.4
|
21.2 units on a scale
Standard Deviation 22.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C18D1 (n=45, 11)
|
8.1 units on a scale
Standard Deviation 20.3
|
30.3 units on a scale
Standard Deviation 34.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C19D1 (n=40, 9)
|
6.7 units on a scale
Standard Deviation 15.5
|
18.5 units on a scale
Standard Deviation 24.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C20D1 (n=35, 8)
|
9.5 units on a scale
Standard Deviation 22.2
|
25.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C21D1 (n=30, 8)
|
7.8 units on a scale
Standard Deviation 16.8
|
29.2 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C22D1 (n=24, 7)
|
2.8 units on a scale
Standard Deviation 9.4
|
21.4 units on a scale
Standard Deviation 24.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C23D1 (n=23, 4)
|
0.7 units on a scale
Standard Deviation 3.5
|
33.3 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C24D1 (n=20, 3)
|
3.3 units on a scale
Standard Deviation 10.3
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C25D1 (n=18, 3)
|
1.9 units on a scale
Standard Deviation 7.9
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C26D1 (n=14, 3)
|
7.1 units on a scale
Standard Deviation 19.3
|
22.2 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C27D1 (n=14, 2)
|
4.8 units on a scale
Standard Deviation 12.1
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C28D1 (n=11, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C29D1 (n=8, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
66.7 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C31D1 (n=7, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C32D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C34D1 (n=5, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C35D1 (n=4, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Arm or Shoulder: EOT (n=48, 90)
|
11.1 units on a scale
Standard Deviation 21.0
|
21.9 units on a scale
Standard Deviation 28.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: Baseline (n=163, 158)
|
23.1 units on a scale
Standard Deviation 27.3
|
31.4 units on a scale
Standard Deviation 30.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C2D1 (n=153, 125)
|
15.0 units on a scale
Standard Deviation 23.2
|
25.9 units on a scale
Standard Deviation 28.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C3D1 (n=152, 104)
|
11.4 units on a scale
Standard Deviation 20.7
|
21.2 units on a scale
Standard Deviation 27.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C4D1 (n=134, 90)
|
12.7 units on a scale
Standard Deviation 22.7
|
21.5 units on a scale
Standard Deviation 24.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C5D1 (n=123, 73)
|
14.4 units on a scale
Standard Deviation 23.0
|
20.5 units on a scale
Standard Deviation 27.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C6D1 (n=118, 68)
|
10.7 units on a scale
Standard Deviation 18.9
|
18.1 units on a scale
Standard Deviation 26.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C7D1 (n=115, 51)
|
11.3 units on a scale
Standard Deviation 20.7
|
16.3 units on a scale
Standard Deviation 26.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C8D1 (n=111, 42)
|
10.5 units on a scale
Standard Deviation 20.6
|
22.2 units on a scale
Standard Deviation 30.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C9D1 (n=100, 37)
|
10.7 units on a scale
Standard Deviation 21.1
|
24.3 units on a scale
Standard Deviation 31.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C10D1 (n=92, 33)
|
9.8 units on a scale
Standard Deviation 18.8
|
28.3 units on a scale
Standard Deviation 35.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C11D1 (n=83, 25)
|
12.4 units on a scale
Standard Deviation 21.3
|
24.0 units on a scale
Standard Deviation 29.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C12D1 (n=74, 23)
|
12.2 units on a scale
Standard Deviation 20.3
|
24.6 units on a scale
Standard Deviation 30.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C13D1 (n=74, 21)
|
10.8 units on a scale
Standard Deviation 19.2
|
31.7 units on a scale
Standard Deviation 34.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C14D1 (n=66, 19)
|
11.6 units on a scale
Standard Deviation 18.0
|
24.6 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C15D1 (n=61, 16)
|
9.8 units on a scale
Standard Deviation 15.3
|
25.0 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C16D1 (n=53, 12)
|
10.7 units on a scale
Standard Deviation 19.4
|
38.9 units on a scale
Standard Deviation 34.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C17D1 (n=46, 11)
|
13.8 units on a scale
Standard Deviation 19.3
|
24.2 units on a scale
Standard Deviation 21.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C18D1 (n=45, 11)
|
10.4 units on a scale
Standard Deviation 19.9
|
33.3 units on a scale
Standard Deviation 39.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C19D1 (n=40, 9)
|
14.2 units on a scale
Standard Deviation 22.5
|
25.9 units on a scale
Standard Deviation 14.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C20D1 (n=35, 8)
|
13.3 units on a scale
Standard Deviation 20.1
|
29.2 units on a scale
Standard Deviation 21.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C21D1 (n=30, 8)
|
21.1 units on a scale
Standard Deviation 27.0
|
29.2 units on a scale
Standard Deviation 37.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C22D1 (n=24, 7)
|
12.5 units on a scale
Standard Deviation 21.6
|
40.5 units on a scale
Standard Deviation 30.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C23D1 (n=23, 4)
|
5.1 units on a scale
Standard Deviation 11.7
|
41.7 units on a scale
Standard Deviation 31.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C24D1 (n=20, 3)
|
6.7 units on a scale
Standard Deviation 17.4
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C25D1 (n=18, 3)
|
9.3 units on a scale
Standard Deviation 15.4
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C26D1 (n=14, 3)
|
23.8 units on a scale
Standard Deviation 30.5
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C27D1 (n=14, 2)
|
16.7 units on a scale
Standard Deviation 31.4
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C28D1 (n=11, 2)
|
6.1 units on a scale
Standard Deviation 13.5
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C29D1 (n=8, 2)
|
4.2 units on a scale
Standard Deviation 11.8
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C30D1 (n=8, 1)
|
12.5 units on a scale
Standard Deviation 17.3
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 16.3
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C32D1 (n=6, 0)
|
5.6 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C34D1 (n=5, 0)
|
6.7 units on a scale
Standard Deviation 14.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C35D1 (n=4, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Pain in Other Parts: EOT (n=49, 90)
|
18.4 units on a scale
Standard Deviation 29.7
|
29.6 units on a scale
Standard Deviation 34.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C31D1 (n=7, 0)
|
15.9 units on a scale
Standard Deviation 8.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: Baseline (n=164, 162)
|
27.2 units on a scale
Standard Deviation 21.7
|
26.9 units on a scale
Standard Deviation 23.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C2D1 (n=155, 132)
|
17.6 units on a scale
Standard Deviation 18.1
|
28.6 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C3D1 (n=153, 106)
|
17.9 units on a scale
Standard Deviation 17.8
|
28.0 units on a scale
Standard Deviation 25.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C4D1 (n=135, 91)
|
16.2 units on a scale
Standard Deviation 17.5
|
27.5 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C5D1 (n=123, 74)
|
16.9 units on a scale
Standard Deviation 16.7
|
24.8 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C6D1 (n=119, 70)
|
15.2 units on a scale
Standard Deviation 15.8
|
25.2 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C7D1 (n=115, 52)
|
15.6 units on a scale
Standard Deviation 16.5
|
24.4 units on a scale
Standard Deviation 20.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C8D1 (n=111, 43)
|
14.7 units on a scale
Standard Deviation 16.0
|
22.0 units on a scale
Standard Deviation 22.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C9D1 (n=101, 37)
|
13.9 units on a scale
Standard Deviation 15.8
|
19.5 units on a scale
Standard Deviation 19.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C10D1 (n=94, 33)
|
15.4 units on a scale
Standard Deviation 17.0
|
21.5 units on a scale
Standard Deviation 21.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C11D1 (n=84, 25)
|
15.1 units on a scale
Standard Deviation 17.5
|
20.4 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C12D1 (n=76, 23)
|
13.7 units on a scale
Standard Deviation 15.5
|
22.7 units on a scale
Standard Deviation 22.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C13D1 (n=74, 21)
|
12.8 units on a scale
Standard Deviation 14.0
|
26.5 units on a scale
Standard Deviation 25.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C14D1 (n=66, 19)
|
14.8 units on a scale
Standard Deviation 16.9
|
26.3 units on a scale
Standard Deviation 26.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C15D1 (n=62, 16)
|
13.2 units on a scale
Standard Deviation 15.4
|
22.9 units on a scale
Standard Deviation 18.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C16D1 (n=53, 12)
|
12.6 units on a scale
Standard Deviation 11.7
|
22.2 units on a scale
Standard Deviation 18.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C17D1 (n=46, 11)
|
12.3 units on a scale
Standard Deviation 11.5
|
30.3 units on a scale
Standard Deviation 23.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C18D1 (n=45, 11)
|
14.1 units on a scale
Standard Deviation 13.5
|
26.3 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C19D1 (n=40, 9)
|
14.4 units on a scale
Standard Deviation 13.8
|
23.5 units on a scale
Standard Deviation 15.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C20D1 (n=35, 8)
|
13.7 units on a scale
Standard Deviation 12.9
|
34.7 units on a scale
Standard Deviation 24.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C21D1 (n=30, 8)
|
12.6 units on a scale
Standard Deviation 13.0
|
25.0 units on a scale
Standard Deviation 14.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C22D1 (n=24, 7)
|
10.6 units on a scale
Standard Deviation 11.1
|
27.0 units on a scale
Standard Deviation 21.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C23D1 (n=23, 4)
|
13.8 units on a scale
Standard Deviation 14.2
|
52.8 units on a scale
Standard Deviation 19.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C24D1 (n=20, 3)
|
14.4 units on a scale
Standard Deviation 14.9
|
48.1 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C25D1 (n=18, 3)
|
15.4 units on a scale
Standard Deviation 12.1
|
40.7 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C26D1 (n=14, 3)
|
14.3 units on a scale
Standard Deviation 10.2
|
44.4 units on a scale
Standard Deviation 22.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C27D1 (n=14, 2)
|
15.1 units on a scale
Standard Deviation 11.2
|
55.6 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C28D1 (n=11, 2)
|
11.1 units on a scale
Standard Deviation 8.6
|
61.1 units on a scale
Standard Deviation 7.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C29D1 (n=8, 2)
|
12.5 units on a scale
Standard Deviation 11.0
|
50.0 units on a scale
Standard Deviation 7.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C30D1 (n=8, 1)
|
9.7 units on a scale
Standard Deviation 7.1
|
77.8 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C32D1 (n=6, 0)
|
18.5 units on a scale
Standard Deviation 9.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C33D1 (n=6, 0)
|
18.5 units on a scale
Standard Deviation 9.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C34D1 (n=5, 0)
|
20.0 units on a scale
Standard Deviation 5.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C35D1 (n=4, 0)
|
16.7 units on a scale
Standard Deviation 6.4
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C36D1 (n=1, 0)
|
22.2 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: C37D1 (n=1, 0)
|
11.1 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dyspnea: EOT (n=49, 90)
|
21.8 units on a scale
Standard Deviation 19.0
|
35.6 units on a scale
Standard Deviation 26.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: Baseline (n=164, 162)
|
38.2 units on a scale
Standard Deviation 27.4
|
42.2 units on a scale
Standard Deviation 31.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C2D1 (n=155, 132)
|
23.0 units on a scale
Standard Deviation 19.6
|
34.8 units on a scale
Standard Deviation 26.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C3D1 (n=153, 106)
|
23.5 units on a scale
Standard Deviation 21.6
|
32.4 units on a scale
Standard Deviation 27.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C4D1 (n=135, 91)
|
19.8 units on a scale
Standard Deviation 22.4
|
27.1 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C5D1 (n=123, 74)
|
18.4 units on a scale
Standard Deviation 21.0
|
25.7 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C6D1 (n=119, 70)
|
14.6 units on a scale
Standard Deviation 18.2
|
30.0 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C7D1 (n=115, 52)
|
15.9 units on a scale
Standard Deviation 18.4
|
26.3 units on a scale
Standard Deviation 23.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C8D1 (n=111, 43)
|
13.2 units on a scale
Standard Deviation 18.7
|
22.5 units on a scale
Standard Deviation 23.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C9D1 (n=101, 37)
|
13.5 units on a scale
Standard Deviation 18.4
|
25.2 units on a scale
Standard Deviation 28.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C16D1 (n=53, 12)
|
0.6 units on a scale
Standard Deviation 4.6
|
5.6 units on a scale
Standard Deviation 13.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C17D1 (n=47, 11)
|
0.0 units on a scale
Standard Deviation 0.0
|
9.1 units on a scale
Standard Deviation 21.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C18D1 (n=45, 11)
|
1.5 units on a scale
Standard Deviation 6.9
|
3.0 units on a scale
Standard Deviation 10.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C19D1 (n=40, 9)
|
0.0 units on a scale
Standard Deviation 0.0
|
3.7 units on a scale
Standard Deviation 11.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C20D1 (n=35, 8)
|
1.0 units on a scale
Standard Deviation 5.6
|
8.3 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C21D1 (n=30, 8)
|
0.0 units on a scale
Standard Deviation 0.0
|
4.2 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C22D1 (n=24, 7)
|
0.0 units on a scale
Standard Deviation 0.0
|
9.5 units on a scale
Standard Deviation 16.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C23D1 (n=23, 4)
|
1.4 units on a scale
Standard Deviation 7.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C24D1 (n=20, 3)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C25D1 (n=18, 3)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C26D1 (n=14, 3)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C27D1 (n=14, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C10D1 (n=94, 33)
|
14.2 units on a scale
Standard Deviation 19.2
|
20.2 units on a scale
Standard Deviation 26.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C11D1 (n=83, 25)
|
12.9 units on a scale
Standard Deviation 20.7
|
18.7 units on a scale
Standard Deviation 25.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C12D1 (n=76, 23)
|
14.5 units on a scale
Standard Deviation 20.6
|
23.2 units on a scale
Standard Deviation 25.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C13D1 (n=74, 21)
|
14.0 units on a scale
Standard Deviation 21.4
|
27.0 units on a scale
Standard Deviation 27.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C14D1 (n=66, 19)
|
13.1 units on a scale
Standard Deviation 19.3
|
24.6 units on a scale
Standard Deviation 31.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C15D1 (n=62, 16)
|
11.8 units on a scale
Standard Deviation 21.0
|
20.8 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C16D1 (n=53, 12)
|
13.8 units on a scale
Standard Deviation 19.0
|
22.2 units on a scale
Standard Deviation 21.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C17D1 (n=47, 11)
|
6.4 units on a scale
Standard Deviation 15.0
|
27.3 units on a scale
Standard Deviation 25.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C18D1 (n=45, 11)
|
13.3 units on a scale
Standard Deviation 18.0
|
18.2 units on a scale
Standard Deviation 17.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C19D1 (n=40, 9)
|
12.5 units on a scale
Standard Deviation 18.0
|
14.8 units on a scale
Standard Deviation 17.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C20D1 (n=35, 8)
|
10.5 units on a scale
Standard Deviation 15.7
|
29.2 units on a scale
Standard Deviation 21.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C21D1 (n=30, 8)
|
13.3 units on a scale
Standard Deviation 24.1
|
33.3 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C22D1 (n=24, 7)
|
8.3 units on a scale
Standard Deviation 14.7
|
28.6 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C23D1 (n=23, 4)
|
11.6 units on a scale
Standard Deviation 19.1
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C24D1 (n=20, 3)
|
8.3 units on a scale
Standard Deviation 14.8
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C25D1 (n=18, 3)
|
5.6 units on a scale
Standard Deviation 12.8
|
44.4 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C26D1 (n=14, 3)
|
2.4 units on a scale
Standard Deviation 8.9
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C27D1 (n=14, 2)
|
7.1 units on a scale
Standard Deviation 14.2
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C28D1 (n=11, 2)
|
18.2 units on a scale
Standard Deviation 31.1
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C29D1 (n=8, 2)
|
8.3 units on a scale
Standard Deviation 15.4
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C30D1 (n=8, 1)
|
20.8 units on a scale
Standard Deviation 24.8
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C31D1 (n=7, 0)
|
19.0 units on a scale
Standard Deviation 17.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C32D1 (n=6, 0)
|
16.7 units on a scale
Standard Deviation 27.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 17.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C34D1 (n=5, 0)
|
20.0 units on a scale
Standard Deviation 29.8
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C35D1 (n=4, 0)
|
33.3 units on a scale
Standard Deviation 47.1
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C36D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: C37D1 (n=1, 0)
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Coughing: EOT (n=49, 90)
|
25.9 units on a scale
Standard Deviation 23.8
|
37.4 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: Baseline (n=164, 162)
|
2.4 units on a scale
Standard Deviation 9.5
|
3.7 units on a scale
Standard Deviation 12.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C2D1 (n=155, 132)
|
1.7 units on a scale
Standard Deviation 7.4
|
3.5 units on a scale
Standard Deviation 12.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C3D1 (n=153, 106)
|
0.9 units on a scale
Standard Deviation 5.3
|
2.2 units on a scale
Standard Deviation 8.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C4D1 (n=135, 91)
|
1.0 units on a scale
Standard Deviation 5.7
|
1.5 units on a scale
Standard Deviation 6.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C5D1 (n=123, 74)
|
0.3 units on a scale
Standard Deviation 3.0
|
0.9 units on a scale
Standard Deviation 5.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C6D1 (n=119, 70)
|
0.6 units on a scale
Standard Deviation 4.3
|
3.8 units on a scale
Standard Deviation 14.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C7D1 (n=115, 52)
|
0.0 units on a scale
Standard Deviation 0.0
|
1.3 units on a scale
Standard Deviation 9.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C8D1 (n=111, 43)
|
0.9 units on a scale
Standard Deviation 7.0
|
2.3 units on a scale
Standard Deviation 11.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C9D1 (n=101, 37)
|
0.3 units on a scale
Standard Deviation 3.3
|
2.7 units on a scale
Standard Deviation 12.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C10D1 (n=94, 33)
|
0.4 units on a scale
Standard Deviation 3.4
|
3.0 units on a scale
Standard Deviation 17.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C11D1 (n=83, 25)
|
2.4 units on a scale
Standard Deviation 11.4
|
4.0 units on a scale
Standard Deviation 14.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C12D1 (n=76, 23)
|
0.9 units on a scale
Standard Deviation 5.4
|
5.8 units on a scale
Standard Deviation 21.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C13D1 (n=74, 21)
|
2.3 units on a scale
Standard Deviation 10.1
|
4.8 units on a scale
Standard Deviation 15.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C14D1 (n=66, 19)
|
0.5 units on a scale
Standard Deviation 4.1
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C15D1 (n=62, 16)
|
1.1 units on a scale
Standard Deviation 5.9
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C28D1 (n=11, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C29D1 (n=8, 2)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C30D1 (n=8, 1)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C31D1 (n=7, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C32D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C34D1 (n=5, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C35D1 (n=4, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Hemoptysis: EOT (n=49, 90)
|
0.7 units on a scale
Standard Deviation 4.8
|
4.8 units on a scale
Standard Deviation 13.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: Baseline (n=164, 162)
|
5.5 units on a scale
Standard Deviation 15.3
|
6.4 units on a scale
Standard Deviation 18.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C2D1 (n=155, 132)
|
8.0 units on a scale
Standard Deviation 17.9
|
9.1 units on a scale
Standard Deviation 18.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C3D1 (n=153, 106)
|
7.0 units on a scale
Standard Deviation 14.6
|
9.4 units on a scale
Standard Deviation 21.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C4D1 (n=135, 91)
|
8.1 units on a scale
Standard Deviation 16.5
|
10.3 units on a scale
Standard Deviation 21.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C5D1 (n=123, 73)
|
5.1 units on a scale
Standard Deviation 12.1
|
9.6 units on a scale
Standard Deviation 20.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C6D1 (n=119, 70)
|
4.8 units on a scale
Standard Deviation 13.9
|
10.5 units on a scale
Standard Deviation 19.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C7D1 (n=115, 52)
|
5.2 units on a scale
Standard Deviation 15.0
|
7.7 units on a scale
Standard Deviation 15.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C8D1 (n=111, 43)
|
3.0 units on a scale
Standard Deviation 9.6
|
10.9 units on a scale
Standard Deviation 18.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C9D1 (n=101, 37)
|
4.8 units on a scale
Standard Deviation 12.5
|
10.8 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C10D1 (n=94, 33)
|
6.4 units on a scale
Standard Deviation 14.9
|
12.1 units on a scale
Standard Deviation 23.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C11D1 (n=84, 25)
|
4.8 units on a scale
Standard Deviation 14.8
|
9.3 units on a scale
Standard Deviation 18.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C12D1 (n=76, 23)
|
3.9 units on a scale
Standard Deviation 12.1
|
8.7 units on a scale
Standard Deviation 18.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C13D1 (n=74, 21)
|
4.5 units on a scale
Standard Deviation 12.7
|
9.5 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C14D1 (n=66, 19)
|
4.5 units on a scale
Standard Deviation 12.9
|
7.0 units on a scale
Standard Deviation 14.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C15D1 (n=62, 16)
|
5.4 units on a scale
Standard Deviation 12.4
|
14.6 units on a scale
Standard Deviation 29.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C16D1 (n=53, 12)
|
6.3 units on a scale
Standard Deviation 14.7
|
8.3 units on a scale
Standard Deviation 15.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C17D1 (n=47, 11)
|
3.5 units on a scale
Standard Deviation 10.4
|
6.1 units on a scale
Standard Deviation 13.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C18D1 (n=45, 11)
|
5.2 units on a scale
Standard Deviation 12.2
|
12.1 units on a scale
Standard Deviation 16.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C19D1 (n=40, 9)
|
4.2 units on a scale
Standard Deviation 11.2
|
7.4 units on a scale
Standard Deviation 14.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C20D1 (n=35, 8)
|
7.6 units on a scale
Standard Deviation 16.3
|
12.5 units on a scale
Standard Deviation 24.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C21D1 (n=30, 8)
|
4.4 units on a scale
Standard Deviation 11.5
|
4.2 units on a scale
Standard Deviation 11.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C22D1 (n=24, 7)
|
5.6 units on a scale
Standard Deviation 12.7
|
7.1 units on a scale
Standard Deviation 13.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C23D1 (n=23, 4)
|
5.1 units on a scale
Standard Deviation 11.7
|
16.7 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C24D1 (n=20, 3)
|
6.7 units on a scale
Standard Deviation 17.4
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C25D1 (n=18, 3)
|
0.0 units on a scale
Standard Deviation 0.0
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C26D1 (n=14, 3)
|
4.8 units on a scale
Standard Deviation 17.8
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C27D1 (n=14, 2)
|
7.1 units on a scale
Standard Deviation 19.3
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C28D1 (n=11, 2)
|
6.1 units on a scale
Standard Deviation 20.1
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C29D1 (n=8, 2)
|
8.3 units on a scale
Standard Deviation 15.4
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C30D1 (n=8, 1)
|
8.3 units on a scale
Standard Deviation 23.6
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C31D1 (n=7, 0)
|
9.5 units on a scale
Standard Deviation 25.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C32D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C34D1 (n=5, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C35D1 (n=4, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Sore Mouth: EOT (n=49, 90)
|
3.4 units on a scale
Standard Deviation 10.2
|
8.1 units on a scale
Standard Deviation 18.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: Baseline (n=164, 162)
|
7.1 units on a scale
Standard Deviation 16.4
|
8.6 units on a scale
Standard Deviation 20.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C2D1 (n=155, 132)
|
8.2 units on a scale
Standard Deviation 15.4
|
9.8 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C3D1 (n=153, 106)
|
7.6 units on a scale
Standard Deviation 16.4
|
9.7 units on a scale
Standard Deviation 20.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C4D1 (n=135, 91)
|
6.2 units on a scale
Standard Deviation 15.3
|
8.1 units on a scale
Standard Deviation 19.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C5D1 (n=123, 74)
|
6.0 units on a scale
Standard Deviation 14.8
|
7.7 units on a scale
Standard Deviation 17.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C6D1 (n=119, 70)
|
7.0 units on a scale
Standard Deviation 15.0
|
10.0 units on a scale
Standard Deviation 16.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C7D1 (n=115, 52)
|
4.1 units on a scale
Standard Deviation 11.8
|
5.1 units on a scale
Standard Deviation 13.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C8D1 (n=111, 43)
|
3.2 units on a scale
Standard Deviation 11.1
|
6.2 units on a scale
Standard Deviation 15.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C9D1 (n=101, 37)
|
5.0 units on a scale
Standard Deviation 11.9
|
7.2 units on a scale
Standard Deviation 16.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C10D1 (n=94, 33)
|
4.3 units on a scale
Standard Deviation 12.2
|
6.1 units on a scale
Standard Deviation 13.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C11D1 (n=84, 25)
|
3.2 units on a scale
Standard Deviation 9.8
|
4.0 units on a scale
Standard Deviation 11.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C12D1 (n=76, 23)
|
3.5 units on a scale
Standard Deviation 10.3
|
7.2 units on a scale
Standard Deviation 17.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C13D1 (n=74, 21)
|
4.1 units on a scale
Standard Deviation 11.0
|
6.3 units on a scale
Standard Deviation 13.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C14D1 (n=66, 19)
|
3.0 units on a scale
Standard Deviation 11.3
|
7.0 units on a scale
Standard Deviation 14.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C15D1 (n=62, 16)
|
3.8 units on a scale
Standard Deviation 13.6
|
4.2 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C16D1 (n=53, 12)
|
4.4 units on a scale
Standard Deviation 11.4
|
2.8 units on a scale
Standard Deviation 9.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C17D1 (n=47, 11)
|
2.8 units on a scale
Standard Deviation 9.4
|
6.1 units on a scale
Standard Deviation 13.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C18D1 (n=45, 11)
|
3.7 units on a scale
Standard Deviation 10.6
|
3.0 units on a scale
Standard Deviation 10.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C19D1 (n=40, 9)
|
4.2 units on a scale
Standard Deviation 11.2
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C20D1 (n=35, 8)
|
4.8 units on a scale
Standard Deviation 14.3
|
8.3 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C21D1 (n=30, 8)
|
3.3 units on a scale
Standard Deviation 10.2
|
8.3 units on a scale
Standard Deviation 15.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C22D1 (n=24, 7)
|
2.8 units on a scale
Standard Deviation 9.4
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C23D1 (n=23, 4)
|
2.9 units on a scale
Standard Deviation 9.6
|
8.3 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C24D1 (n=20, 3)
|
5.0 units on a scale
Standard Deviation 22.4
|
0.0 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C25D1 (n=18, 3)
|
0.0 units on a scale
Standard Deviation 0.0
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C26D1 (n=14, 3)
|
9.5 units on a scale
Standard Deviation 27.5
|
11.1 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C27D1 (n=14, 2)
|
2.4 units on a scale
Standard Deviation 8.9
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C28D1 (n=11, 2)
|
6.1 units on a scale
Standard Deviation 13.5
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C29D1 (n=8, 2)
|
8.3 units on a scale
Standard Deviation 15.4
|
16.7 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C30D1 (n=8, 1)
|
0.0 units on a scale
Standard Deviation 0.0
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C31D1 (n=7, 0)
|
4.8 units on a scale
Standard Deviation 12.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C32D1 (n=6, 0)
|
5.6 units on a scale
Standard Deviation 13.6
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C33D1 (n=6, 0)
|
0.0 units on a scale
Standard Deviation 0.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C34D1 (n=5, 0)
|
6.7 units on a scale
Standard Deviation 14.9
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C35D1 (n=4, 0)
|
8.3 units on a scale
Standard Deviation 16.7
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Dysphagia: EOT (n=49, 90)
|
4.8 units on a scale
Standard Deviation 13.6
|
8.5 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: Baseline (n=164, 162)
|
14.0 units on a scale
Standard Deviation 22.1
|
17.7 units on a scale
Standard Deviation 27.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C2D1 (n=155, 132)
|
18.1 units on a scale
Standard Deviation 24.1
|
21.5 units on a scale
Standard Deviation 29.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C3D1 (n=153, 106)
|
17.6 units on a scale
Standard Deviation 26.2
|
18.2 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C4D1 (n=134, 91)
|
15.9 units on a scale
Standard Deviation 23.0
|
21.6 units on a scale
Standard Deviation 27.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C5D1 (n=123, 74)
|
15.2 units on a scale
Standard Deviation 21.0
|
21.2 units on a scale
Standard Deviation 28.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C6D1 (n=119, 70)
|
13.7 units on a scale
Standard Deviation 21.9
|
18.1 units on a scale
Standard Deviation 27.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C7D1 (n=115, 52)
|
13.0 units on a scale
Standard Deviation 21.0
|
21.8 units on a scale
Standard Deviation 28.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C8D1 (n=111, 43)
|
10.8 units on a scale
Standard Deviation 20.2
|
24.0 units on a scale
Standard Deviation 32.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C9D1 (n=101, 37)
|
11.2 units on a scale
Standard Deviation 19.6
|
29.7 units on a scale
Standard Deviation 34.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C10D1 (n=94, 33)
|
11.3 units on a scale
Standard Deviation 21.1
|
27.3 units on a scale
Standard Deviation 29.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C11D1 (n=84, 25)
|
11.1 units on a scale
Standard Deviation 21.5
|
24.0 units on a scale
Standard Deviation 31.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C12D1 (n=76, 23)
|
11.4 units on a scale
Standard Deviation 22.1
|
33.3 units on a scale
Standard Deviation 36.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C13D1 (n=74, 21)
|
10.4 units on a scale
Standard Deviation 19.1
|
33.3 units on a scale
Standard Deviation 35.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C14D1 (n=66, 19)
|
10.6 units on a scale
Standard Deviation 21.2
|
29.8 units on a scale
Standard Deviation 35.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C15D1 (n=62, 16)
|
8.6 units on a scale
Standard Deviation 18.0
|
25.0 units on a scale
Standard Deviation 31.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C16D1 (n=52, 12)
|
10.3 units on a scale
Standard Deviation 19.3
|
25.0 units on a scale
Standard Deviation 20.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C17D1 (n=47, 11)
|
12.1 units on a scale
Standard Deviation 23.5
|
27.3 units on a scale
Standard Deviation 29.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C18D1 (n=45, 11)
|
11.9 units on a scale
Standard Deviation 22.6
|
30.3 units on a scale
Standard Deviation 31.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C19D1 (n=40, 9)
|
9.2 units on a scale
Standard Deviation 20.0
|
22.2 units on a scale
Standard Deviation 16.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C20D1 (n=35, 8)
|
12.4 units on a scale
Standard Deviation 25.7
|
33.3 units on a scale
Standard Deviation 30.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C21D1 (n=30, 8)
|
11.1 units on a scale
Standard Deviation 18.2
|
29.2 units on a scale
Standard Deviation 21.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C22D1 (n=24, 7)
|
8.3 units on a scale
Standard Deviation 20.3
|
28.6 units on a scale
Standard Deviation 23.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C23D1 (n=23, 4)
|
8.7 units on a scale
Standard Deviation 20.6
|
41.7 units on a scale
Standard Deviation 31.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C24D1 (n=20, 3)
|
3.3 units on a scale
Standard Deviation 14.9
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C25D1 (n=18, 3)
|
9.3 units on a scale
Standard Deviation 19.2
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C26D1 (n=14, 3)
|
16.7 units on a scale
Standard Deviation 36.4
|
22.2 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C27D1 (n=14, 2)
|
9.5 units on a scale
Standard Deviation 20.4
|
66.7 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C28D1 (n=11, 2)
|
15.2 units on a scale
Standard Deviation 22.9
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C29D1 (n=8, 2)
|
12.5 units on a scale
Standard Deviation 24.8
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C30D1 (n=8, 1)
|
16.7 units on a scale
Standard Deviation 30.9
|
33.3 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C31D1 (n=7, 0)
|
19.0 units on a scale
Standard Deviation 32.5
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C32D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 27.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C33D1 (n=6, 0)
|
11.1 units on a scale
Standard Deviation 27.2
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C35D1 (n=4, 0)
|
25.0 units on a scale
Standard Deviation 50.0
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C36D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: C37D1 (n=1, 0)
|
0.0 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable.
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable.
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Peripheral Neuropathy: EOT (n=49, 90)
|
10.2 units on a scale
Standard Deviation 16.9
|
21.9 units on a scale
Standard Deviation 29.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: Baseline (n=163, 162)
|
17.4 units on a scale
Standard Deviation 30.6
|
16.9 units on a scale
Standard Deviation 29.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C2D1 (n=155, 132)
|
9.5 units on a scale
Standard Deviation 21.4
|
36.6 units on a scale
Standard Deviation 39.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C3D1 (n=153, 106)
|
7.6 units on a scale
Standard Deviation 18.1
|
30.5 units on a scale
Standard Deviation 36.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C4D1 (n=135, 91)
|
8.9 units on a scale
Standard Deviation 22.0
|
24.9 units on a scale
Standard Deviation 32.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C5D1 (n=123, 74)
|
6.0 units on a scale
Standard Deviation 17.1
|
23.9 units on a scale
Standard Deviation 31.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C6D1 (n=118, 70)
|
4.2 units on a scale
Standard Deviation 14.8
|
23.3 units on a scale
Standard Deviation 32.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C7D1 (n=115, 52)
|
4.9 units on a scale
Standard Deviation 14.1
|
19.9 units on a scale
Standard Deviation 30.4
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C8D1 (n=111, 43)
|
3.9 units on a scale
Standard Deviation 11.7
|
18.6 units on a scale
Standard Deviation 28.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C9D1 (n=101, 37)
|
4.0 units on a scale
Standard Deviation 11.8
|
16.2 units on a scale
Standard Deviation 23.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C10D1 (n=94, 33)
|
4.6 units on a scale
Standard Deviation 14.3
|
14.1 units on a scale
Standard Deviation 22.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C11D1 (n=84, 25)
|
4.0 units on a scale
Standard Deviation 15.0
|
16.0 units on a scale
Standard Deviation 21.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C12D1 (n=76, 23)
|
4.4 units on a scale
Standard Deviation 14.7
|
20.3 units on a scale
Standard Deviation 26.1
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C13D1 (n=74, 21)
|
6.3 units on a scale
Standard Deviation 18.0
|
12.7 units on a scale
Standard Deviation 19.7
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C14D1 (n=65, 19)
|
3.6 units on a scale
Standard Deviation 14.6
|
15.8 units on a scale
Standard Deviation 23.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C15D1 (n=62, 16)
|
4.8 units on a scale
Standard Deviation 16.9
|
8.3 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C16D1 (n=53, 12)
|
6.3 units on a scale
Standard Deviation 18.6
|
13.9 units on a scale
Standard Deviation 22.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C17D1 (n=46, 11)
|
5.1 units on a scale
Standard Deviation 17.2
|
18.2 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C18D1 (n=45, 11)
|
3.7 units on a scale
Standard Deviation 12.8
|
18.2 units on a scale
Standard Deviation 22.9
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C19D1 (n=40, 9)
|
5.8 units on a scale
Standard Deviation 19.8
|
18.5 units on a scale
Standard Deviation 24.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C20D1 (n=35, 8)
|
3.8 units on a scale
Standard Deviation 13.5
|
25.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C21D1 (n=30, 8)
|
7.8 units on a scale
Standard Deviation 22.6
|
16.7 units on a scale
Standard Deviation 25.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C22D1 (n=24, 7)
|
2.8 units on a scale
Standard Deviation 9.4
|
14.3 units on a scale
Standard Deviation 17.8
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C23D1 (n=23, 3)
|
1.4 units on a scale
Standard Deviation 7.0
|
22.2 units on a scale
Standard Deviation 19.2
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C24D1 (n=20, 3)
|
6.7 units on a scale
Standard Deviation 23.2
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C25D1 (n=18, 3)
|
9.3 units on a scale
Standard Deviation 27.5
|
33.3 units on a scale
Standard Deviation 33.3
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C26D1 (n=14, 3)
|
7.1 units on a scale
Standard Deviation 26.7
|
44.4 units on a scale
Standard Deviation 38.5
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C27D1 (n=14, 2)
|
16.7 units on a scale
Standard Deviation 36.4
|
33.3 units on a scale
Standard Deviation 0.0
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C28D1 (n=11, 2)
|
6.1 units on a scale
Standard Deviation 20.1
|
50.0 units on a scale
Standard Deviation 23.6
|
|
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
Alopecia: C29D1 (n=8, 2)
|
16.7 units on a scale
Standard Deviation 35.6
|
33.3 units on a scale
Standard Deviation 0.0
|
SECONDARY outcome
Timeframe: Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks)Population: FAS included all participants who were randomized to study treatment. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure and "n" signifies participants who were evaluable for specified time points for each arm group, respectively.
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Outcome measures
| Measure |
Crizotinib
n=164 Participants
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=161 Participants
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C14D1 (n=66, 19)
|
78.77 units on a scale
Standard Deviation 15.54
|
74.11 units on a scale
Standard Deviation 22.56
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
Baseline (n=164, 161)
|
64.09 units on a scale
Standard Deviation 21.04
|
66.76 units on a scale
Standard Deviation 20.74
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C2D1 (n=153, 131)
|
69.19 units on a scale
Standard Deviation 19.42
|
66.33 units on a scale
Standard Deviation 20.30
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C3D1 (n=153, 105)
|
73.13 units on a scale
Standard Deviation 18.97
|
65.84 units on a scale
Standard Deviation 20.80
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C4D1 (n=135, 90)
|
73.78 units on a scale
Standard Deviation 18.25
|
69.13 units on a scale
Standard Deviation 18.14
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C5D1 (n=122, 74)
|
75.27 units on a scale
Standard Deviation 17.99
|
68.12 units on a scale
Standard Deviation 23.19
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C6D1 (n=120, 70)
|
75.79 units on a scale
Standard Deviation 18.67
|
69.71 units on a scale
Standard Deviation 22.46
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C7D1 (n=115, 52)
|
77.02 units on a scale
Standard Deviation 17.34
|
70.63 units on a scale
Standard Deviation 24.31
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C8D1 (n=110, 43)
|
74.72 units on a scale
Standard Deviation 18.09
|
72.30 units on a scale
Standard Deviation 23.54
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C9D1 (n=101, 37)
|
74.45 units on a scale
Standard Deviation 18.32
|
72.27 units on a scale
Standard Deviation 25.85
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C10D1 (n=94, 33)
|
75.49 units on a scale
Standard Deviation 18.18
|
74.27 units on a scale
Standard Deviation 24.88
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C11D1 (n=84, 25)
|
76.32 units on a scale
Standard Deviation 17.00
|
77.24 units on a scale
Standard Deviation 20.31
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C12D1 (n=77, 23)
|
76.95 units on a scale
Standard Deviation 17.63
|
74.83 units on a scale
Standard Deviation 22.60
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C13D1 (n=73, 21)
|
76.38 units on a scale
Standard Deviation 17.50
|
73.00 units on a scale
Standard Deviation 23.54
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C15D1 (n=62, 16)
|
77.71 units on a scale
Standard Deviation 16.78
|
77.44 units on a scale
Standard Deviation 19.52
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C16D1 (n=53, 12)
|
75.32 units on a scale
Standard Deviation 16.21
|
79.00 units on a scale
Standard Deviation 13.28
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C17D1 (n=47, 11)
|
75.09 units on a scale
Standard Deviation 17.68
|
81.73 units on a scale
Standard Deviation 15.98
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C18D1 (n=45, 11)
|
75.87 units on a scale
Standard Deviation 16.63
|
78.91 units on a scale
Standard Deviation 16.25
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C19D1 (n=40, 9)
|
76.85 units on a scale
Standard Deviation 16.39
|
78.00 units on a scale
Standard Deviation 14.04
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C20D1 (n=35, 8)
|
72.66 units on a scale
Standard Deviation 19.81
|
76.75 units on a scale
Standard Deviation 17.65
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C21D1 (n=30, 8)
|
74.13 units on a scale
Standard Deviation 16.19
|
73.63 units on a scale
Standard Deviation 19.41
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C22D1 (n=24, 7)
|
77.54 units on a scale
Standard Deviation 17.54
|
72.21 units on a scale
Standard Deviation 19.79
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C23D1 (n=23, 4)
|
75.48 units on a scale
Standard Deviation 17.75
|
54.00 units on a scale
Standard Deviation 16.35
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C24D1 (n=20, 3)
|
71.40 units on a scale
Standard Deviation 23.15
|
62.00 units on a scale
Standard Deviation 20.30
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C25D1 (n=18, 3)
|
75.61 units on a scale
Standard Deviation 15.97
|
63.67 units on a scale
Standard Deviation 22.59
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C26D1 (n=14, 3)
|
72.14 units on a scale
Standard Deviation 20.71
|
63.00 units on a scale
Standard Deviation 17.52
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C27D1 (n=14, 2)
|
66.57 units on a scale
Standard Deviation 16.96
|
50.00 units on a scale
Standard Deviation 14.14
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C28D1 (n=11, 2)
|
72.36 units on a scale
Standard Deviation 12.72
|
55.00 units on a scale
Standard Deviation 21.21
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C29D1 (n=8, 2)
|
71.38 units on a scale
Standard Deviation 12.28
|
45.00 units on a scale
Standard Deviation 14.14
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C30D1 (n=8, 1)
|
69.50 units on a scale
Standard Deviation 17.00
|
40.00 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C31D1 (n=7, 0)
|
68.57 units on a scale
Standard Deviation 16.76
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C32D1 (n=6, 0)
|
65.83 units on a scale
Standard Deviation 19.41
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C33D1 (n=6, 0)
|
67.50 units on a scale
Standard Deviation 20.34
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C34D1 (n=5, 0)
|
68.00 units on a scale
Standard Deviation 20.80
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C35D1 (n=4, 0)
|
72.25 units on a scale
Standard Deviation 14.84
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C36D1 (n=1, 0)
|
90.00 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
C37D1 (n=1, 0)
|
85.00 units on a scale
Standard Deviation NA
Standard deviation was not estimable since only one participant was evaluable
|
NA units on a scale
Standard Deviation NA
Data was not analyzed as no participants were evaluable
|
|
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
EOT (n=49, 90)
|
68.33 units on a scale
Standard Deviation 21.25
|
58.34 units on a scale
Standard Deviation 23.71
|
Adverse Events
Crizotinib
Serious events: 80 serious events
Other events: 172 other events
Deaths: 0 deaths
Chemotherapy
Serious events: 42 serious events
Other events: 169 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Crizotinib
n=172 participants at risk
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=171 participants at risk
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
General disorders
Product contamination microbial
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Anaemia
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.0%
12/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Neutropenia
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Arrhythmia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Cardiac arrest
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Cardiac tamponade
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Pericardial effusion
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Ileus paralytic
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Nausea
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Vomiting
|
1.7%
3/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Chest pain
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Death
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Disease progression
|
10.5%
18/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Fatigue
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Pyrexia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Sudden death
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Hepatobiliary disorders
Hepatitis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Empyema
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Extradural abscess
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Lower respiratory tract infection
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Lung abscess
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Lung infection
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Pneumonia
|
4.7%
8/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Pneumonia bacterial
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Sepsis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Alanine aminotransferase increased
|
1.7%
3/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Aspartate aminotransferase increased
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Blood glucose increased
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Haemoglobin
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Brain oedema
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Headache
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Intracranial pressure increased
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Lethargy
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Paraesthesia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Presyncope
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Psychiatric disorders
Mental status changes
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Renal and urinary disorders
Renal cyst
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
3.5%
6/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
1.7%
3/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Organising pneumonia
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary artery thrombosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
4.1%
7/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Surgical and medical procedures
Cancer surgery
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Vascular disorders
Deep vein thrombosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Vascular disorders
Pelvic venous thrombosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Coronary artery disease
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Syncope
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Food poisoning
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Haematemesis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
General physical health deterioration
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Malaise
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Cellulitis
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Gastroenteritis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Pneumonia influenzal
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer recurrent
|
0.00%
0/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Cerebral cyst
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Dizziness
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Seizure
|
1.2%
2/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Psychiatric disorders
Delirium
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Renal and urinary disorders
Ureteric stenosis
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
Other adverse events
| Measure |
Crizotinib
n=172 participants at risk
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
Chemotherapy
n=171 participants at risk
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
|
|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
20.9%
36/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
15.8%
27/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Leukopenia
|
14.0%
24/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Eye disorders
Photopsia
|
12.2%
21/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Eye disorders
Vision blurred
|
7.6%
13/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
2.9%
5/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Eye disorders
Visual impairment
|
43.0%
74/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.7%
8/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Abdominal pain
|
10.5%
18/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.7%
8/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
9.9%
17/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Constipation
|
48.3%
83/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
22.8%
39/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Diarrhoea
|
61.6%
106/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
19.9%
34/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Dyspepsia
|
10.5%
18/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
3.5%
6/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Nausea
|
60.5%
104/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
35.1%
60/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Stomatitis
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Vomiting
|
51.2%
88/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
18.7%
32/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Asthenia
|
18.0%
31/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
18.7%
32/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Chest pain
|
8.7%
15/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Fatigue
|
29.7%
51/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
35.1%
60/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Oedema
|
8.7%
15/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
3.5%
6/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Oedema peripheral
|
34.3%
59/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
8.8%
15/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Pyrexia
|
23.8%
41/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
19.3%
33/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Nasopharyngitis
|
18.6%
32/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.1%
7/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Infections and infestations
Upper respiratory tract infection
|
14.0%
24/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
8.2%
14/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Alanine aminotransferase increased
|
41.9%
72/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
12.3%
21/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Aspartate aminotransferase increased
|
32.0%
55/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
9.9%
17/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Blood alkaline phosphatase increased
|
10.5%
18/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
3.5%
6/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Blood creatinine increased
|
7.6%
13/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Neutrophil count decreased
|
8.7%
15/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Weight decreased
|
12.2%
21/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.7%
8/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
White blood cell count decreased
|
9.3%
16/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
32.6%
56/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
26.9%
46/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
7.0%
12/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
9.3%
16/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.58%
1/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
8.7%
15/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
2.9%
5/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
8.7%
15/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
11.7%
20/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
17.4%
30/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
6.4%
11/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
8.1%
14/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
3.5%
6/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
2.9%
5/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
11.1%
19/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
11.6%
20/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.8%
10/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Dizziness
|
19.8%
34/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Dysgeusia
|
26.2%
45/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
9.9%
17/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Headache
|
26.7%
46/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
15.2%
26/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Neuropathy peripheral
|
2.9%
5/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.8%
10/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Paraesthesia
|
7.6%
13/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.1%
7/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Psychiatric disorders
Insomnia
|
11.0%
19/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
7.6%
13/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
21.5%
37/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
20.5%
35/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
15.7%
27/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
17.0%
29/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
1.7%
3/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.8%
10/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
6.4%
11/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
11.6%
20/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.1%
7/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
2.3%
4/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
12.2%
21/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
20.5%
35/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
5.8%
10/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
7.0%
12/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.1%
7/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Skin and subcutaneous tissue disorders
Rash
|
13.4%
23/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
17.5%
30/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Blood and lymphatic system disorders
Neutropenia
|
23.8%
41/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
10.5%
18/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Eye disorders
Lacrimation increased
|
0.58%
1/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Dysphagia
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
7.0%
12/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
General disorders
Pain
|
5.8%
10/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
5.3%
9/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Injury, poisoning and procedural complications
Fall
|
6.4%
11/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.8%
3/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Investigations
Electrocardiogram QT prolonged
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
7.6%
13/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
2.3%
4/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
6.4%
11/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
2.9%
5/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
3.5%
6/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Nervous system disorders
Visual perseveration
|
7.0%
12/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
7.0%
12/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
4.7%
8/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
1.2%
2/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
|
Cardiac disorders
Bradycardia
|
5.2%
9/172 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
0.00%
0/171 • Active reporting period is from the time of informed consent until at least 28 days after the last dose of study treatment.
All causality (serious and non-serious) adverse events have been reported. Non-serious adverse events above the 5% threshold are reported herein.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER